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A B S T R A C T
Background
Soft tissue sarcomas (STS) are a highly heterogeneous group of raremalignant solid tumors.Non-rhabdomyosarcoma soft tissue sarcomas
(NRSTS) comprise all STS except rhabdomyosarcoma. In patients with advanced local or metastatic disease, autologous hematopoietic
stem cell transplantation (HSCT) applied after high-dose chemotherapy (HDCT) is a planned rescue therapy for HDCT-related severe
hematologic toxicity.
Objectives
To assess the effectiveness and safety of HDCT followed by autologous HSCT for all stages of soft tissue sarcomas in children and
adults.
Search methods
We searched the electronic databases CENTRAL (The Cochrane Library 2010, Issue 2), MEDLINE and EMBASE (February 2010).
Online trial registers, congress abstracts and reference lists of reviews were searched and expert panels and authors were contacted.
Selection criteria
Terms representing STS and autologous HSCT were required in the title, abstract or keywords. In studies with aggregated data,
participants with NRSTS and autologous HSCT had to constitute at least 80% of the data. Comparative non-randomized studies were
included because randomized controlled trials (RCTs) were not expected. Case series and case reports were considered for an additional
descriptive analysis.
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Data collection and analysis
Study data were recorded by two review authors independently. For studies with no comparator group, we synthesised results for studies
reporting aggregate data and conducted a pooled analysis of individual participant data using the Kaplan-Meyer method. The primary
outcomes were overall survival (OS) and treatment-related mortality (TRM).
Main results
We included 54 studies, from 467 full texts articles screened (11.5%), reporting on 177 participants that received HSCT and 69
participants that received standard care. Only one study reported comparative data. In the one comparative study, OS at two years after
HSCT was estimated as statistically significantly higher (62.3%) compared with participants that received standard care (23.2%). In a
single-arm study, the OS two years after HSCT was reported as 20%. In a pooled analysis of the individual data of 54 participants, OS
at two years was estimated as 49% (95% CI 34% to 64%). Data on TRM, secondary neoplasia and severe toxicity grade 3 to 4 after
transplantation were sparse. All 54 studies had a high risk of bias.
Authors’ conclusions
Due to a lack of comparative studies, it is unclear whether participants with NRSTS have improved survival from autologous HSCT
following HDCT. Owing to this current gap in knowledge, at present HDCT and autologous HSCT for NRSTS should only be used
within controlled trials.
P L A I N L A N G U A G E S U M M A R Y
Hematopoietic stem cell transplantation following chemotherapy for non-rhabdomyosarcoma soft tissue sarcomas
Non-rhabdomyosarcoma soft tissue sarcomas are a group of rare cancers. Patients with inoperable or metastatic disease have a poor
prognosis. It was believed higher doses of chemotherapy might improve patients’ survival. However, high doses of chemotherapy stop
the production of blood cells in the bone marrow and are not compatible with life. Stem cells collected from patients before high-dose
chemotherapy can be transplanted back to the patient if the blood cell count gets too low. Due to a lack of research studies, it has not
been proven that patients treated with this procedure lived longer than patients treated with standard chemotherapy.
We reviewed the published research on this treatment to investigate how effective and safe it is. Unfortunately we identified only one
comparative study and the results of this study were not credible. Studies with aggregated data showed that two years after treatment
between 20% to 60% of patients were still alive but the treatment had a high level of toxic side effects.
While the results of this systematic review may not be conclusive, they provide a summary of the current knowledge and highlight that
more research is needed. Currently the research evidence says that patients with non-rhabdomyosarcoma soft tissue sarcomas should
only be treated with high-dose chemotherapy and then autologous hematopoietic stem cell transplantation except within clinical trials.
B A C K G R O U N D
Description of the condition
Soft tissue sarcomas (STS) are a highly heterogeneous group of
rare malignant solid tumors of non-epithelial extraskeletal body
tissue and are classified on a histogenetic basis (Enzinger 2001).
STS have a significant risk of distant metastasis in addition to the
potential for locally destructive growth and recurrence. Non-rhab-
domyosarcoma soft tissue sarcomas (NRSTS) comprise all STS
except rhabdomyosarcoma, which primarily affects children and
young adults. In this review we investigated NRSTS which are
categorized as malignant according to the World Health Orga-
nization (WHO) 2002 classification (Fletcher 2002) as adopted
by the European Society for Medical Oncology (ESMO) Guide-
lines Working Group (Casali 2009). This classification excludes
the Ewing family of tumors (EFT).
NRSTS usually originate de novo and rarely from benign tumors.
In most cases the pathogenesis is unknown; however, some factors
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have been found to be associated with the development of NRSTS
(Enzinger 2001). These include exposure to ionizing radiation,
environmental carcinogenic substances, oncogenic viruses and im-
munologic factors. Genetic factors can also play a role since some
inherited diseases such as neurofibromatosis type 1 are associated
with a higher risk of NRSTS (Tsao 2000).
In Western countries about four new cases of NRSTS are esti-
mated per 100,000population every year (Casali 2009), with rhab-
domyosarcoma and the Ewing family of tumors excluded from
this statistic. STS constitute about 1% of malignancies in adults
and 7% in children (NCI 2009a). Rhabdomyosarcoma repre-
sents about 50% of STS in children (Gurney 1997; Miller 1995).
NRSTS are rare in both children and adults and the distribution
of NRSTS differs significantly between children and adults (Table
1) according to (Spunt 2006).
Based on the Surveillance, Epidemiology and End Results (SEER)
cancer statistics review (1975 to 2005) of the National Cancer In-
stitute (NCI), in the US 10,390 new cases and 3680 deaths from
STS were estimated for the year 2008 (NCI 2008a). Separate data
were not available for rhabdomyosarcoma and NRSTS. The dis-
tribution of STS increased with age from 2001 to 2005, according
to SEER data. Of all STS cases, 10.3% were in children and young
adults less than 20 years of age (NCI 2008b). The median age
at diagnosis of STS, including tumors of the heart, was 57 years
(NCI 2008c).
Staging
Disease progression may be dichotomized into the two categories
of limited and extensive disease. Limited disease is typically a lo-
calized, small-sized, low-grade and operable accessible tumor that
has no regional lymph node involvement and no distant metas-
tases. Extensive disease can also be denoted as advanced disease
defined as localized, large-sized and high-grade tumor that may
not be completely removed by surgery, may be invasive and may
have regional lymph node involvement or distant metastases. Both
categories differ significantly in terms of prognosis and treatment.
Wheremany patients with limited diseasemay be cured by surgery,
extensive disease is associated with a poor outcome and many pa-
tients receive chemotherapy as palliative therapy.
The American Joint Committee on Cancer (AJCC) tumor-node-
metastasis (TNM) staging system combines grade, depth and size
of the tumor as well as regional lymph node involvement and dis-
tant metastases and describes the extent of a cancer’s spread from
Stage 0 to IV (AJCC 2002). A review reported the 5-year over-
all survival (OS) estimates for stage I (low-grade, superficial and
deep), II (high-grade, superficial and deep), III (high-grade, large
and deep) and IV (any metastasis to lymph nodes or distant sites)
as approximately 90%, 70%, 50% and 10% to 20%, respectively;
information on treatment was not given (Clark 2005). In a multi-
centre study a total of 2185 participants with advanced STS re-
vealed a median survival of 12 months (Van Glabbeke 1999). In
the same study, of the 1922 (26%) eligible participants who re-
sponded to chemotherapy, the 5-year OS was 10%; in univariate
analyses response to chemotherapy was not predicted by the same
factors as was OS.
Symptoms
The location of the primary tumor can involve any area of the
body. The distribution is 40% lower limb and girdle, 20% upper
limb and girdle, 20% abdominal sites, 10% trunk and 10% head
and neck (Clark 2005). NRSTS can involve any type of tissue
and typically affect muscles, tendons, adipose tissue, blood vessels,
joints (Sondak 2001) and commonly present as a painless mass.
The symptoms depend on the anatomical site of origin, the size
of the mass and other aspects. Retroperitoneal sarcomas are most
often asymptomatic, until the mass grows large enough to be clin-
ically obvious or presses on vital organs and causes pain (Dileo
2005).
Patients who relapse or suffer progressive disease after therapy, or
metastasis, are commonly called high-risk patients because these
signs are associated with shorter survival time. Spontaneous recov-
ery of NRSTS is unknown.
Description of the intervention
Standard therapy
Surgery is the standard treatment for localized NRSTS (Casali
2009) and can be curative if distant dissemination is not present
(Kotilingam 2006). Chemotherapy is a standard treatment for pa-
tients with distant metastasis (Casali 2009) and is regarded mainly
as a palliative treatment for high-risk patients who are character-
ized by inoperable, locally advanced and metastatic disease. Dox-
orubicin, ifosfamide, gemcitabine, dacarbacine, docetaxel and tra-
bectedin are used in monotherapy or in combinations (Casali
2009).
High-dose chemotherapy (HDCT) followed by
autologous hematopoietic stem cell transplantation
(HSCT)
Autologous hematopoietic stem cell transplantation (HSCT) is
defined as the transplantation of stem cells that have been col-
lected previously from bone marrow or peripheral blood of the
same person.High-dose chemotherapy (HDCT) uses higher doses
of chemotherapeutic agents than is usually applied in standard-
dose chemotherapy. HDCT may be tolerated by the patient or it
may ablate the patient’s bone marrow reserves and create an ab-
solute requirement for stem cell rescue. Instead of HDCT, high-
dose radiation therapy may be used to treat NRSTS patients. Au-
tologous HSCT applied after HDCT or high-dose radiation is a
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planned rescue therapy forHDCT-related severe hematologic tox-
icity (Banna 2007). Ideally, amega-therapy regimen should be used
consisting of several non-crossresistant agents that have a steep
dose-response curve and little extramedullary toxicity (Ladenstein
1997).
HDCT and autologous HSCT are not a standard treatment op-
tion; they are an experimental approach. HDCT and autologous
HSCTmaybe used in special cases after careful consideration, usu-
ally for patients who respond well to standard chemotherapy ac-
cording to RECIST (Therasse 2000) criteria (Kasper 2005; Kasper
2007). Carboplatin, cisplatin, cyclophosphamide, etoposide, ifos-
famide, melphalan, mitoxantrone and thiotepa, for example, have
been used in HDCT regimens. HDCT and autologous HSCT are
an experimental approach mainly used to treat high-risk patients
with an unfavourable prognosis (stage IV with distant metastases).
Independent of the disease status, HDCT and autologous HSCT
are hazardous interventions that carry the risk of life-threatening
organ failure.
Autologous HSCT and preceding HDCT were adopted to treat
high-risk patients because it was believed that escalating doses
in chemotherapy might increase survival by capturing putatively
remnant malignant cells and might overcome resistance to stan-
dard-dose chemotherapy (Banna 2007).
Adverse events
Non-hematological adverse events, such as short-term and long-
term organ toxicities, must be considered when using HDCT
(Ladenstein 1997). Hematological adverse events as a result of au-
tologous HSCT are usually manageable but life-threatening con-
sequences of pancytopenia. They generally affect all patients and
include, for example, graft failure, severe infections and bleeding.
Frequency
Of a total of 15,278 autologous HSCTs that were registered in
2005 by the European Group for Blood and Marrow Transplan-
tation (EBMT), 69 were indicated for STS (Gratwohl 2007).
How the intervention might work
Escalating doses of chemotherapymay increase survival by captur-
ing putatively remnant malignant cells and thus overcome cell re-
sistance to standard chemotherapy (Banna 2007). High-dose che-
motherapy may also cause severe hematologic and non-hemato-
logic toxicity. Autologous HSCT is a planned rescue therapy for
the HDCT-related demise of hematopoietic stem cells.
Why it is important to do this review
The potential benefit of this treatment option has not been in-
vestigated sufficiently in comparative studies (Pedrazzoli 2006).
Some authors have warned against the use of HDCT with autol-
ogous HSCT, indicating the possibility of repositioning of malig-
nant cells (Woods 1999). Others have questioned the rationale of
HDCT with reference to the potential existence of refractory can-
cer stem cells (Banna 2007; Bonnet 1997; Sanchez-Garcia 2007).
The question has not been answered whether autologous HSCT
preceded byHDCT is able to increase OS in patients withNRSTS
when compared to standard-dose chemotherapy. Randomized
controlled trials (RCTs) have not been published. The rationale
for this intervention, as described above, was based on non-com-
parative studies. We summarized and described the present avail-
able evidence to provide an evidence base to inform the design of
future comparative studies.
O B J E C T I V E S
To assess the effectiveness and safety of autologous high-dose che-
motherapy (HDCT) followed by autologous hematopoietic stem
cell transplantation (HDCT) for all stages of non-rhabdomyosar-
coma soft tissue sarcomas (NRSTS) in children and adults.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Inclusion criteria
• Randomized controlled trials (RCTs).
Since we expected to find few, if any, RCTs non-RCTs were also
included as follows.
• Quasi-RCTs, non-RCTs, phase I and II prospective studies,
prospective and retrospective cohort studies, case-control studies,
case series and case reports.
Results from RCTs and controlled clinical trials may provide data
for estimation of effects on overall survival (OS) and answer the
question: “Has the intervention a significantly better survival than
the control and does the quality of the studies fit with the assump-
tion that the intervention is better than the control?”
Data from non-comparative studies (phase I and II prospective
studies, case series and case reports)were collected to estimate treat-
ment-related mortality (TRM) within a cohort of participants, as
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a descriptive analysis. Due to the lack of a control group the studies
do not provide data for estimation of treatment effect.
Exclusion criteria
None
Rationale for including non-RCTs
Authors of studies on HDCT with autologous HSCT have stated
that RCTs are both necessary and feasible. However, NRSTS is
a rare disease and, according to the results of a preview literature
search, currently there are no published RCTs available. In ad-
dition, controlled clinical trials or studies with any comparative
data may be unlikely or rare. If they do exist they may be of low
methodological quality. Based on the assumption that it is unlikely
that the intervention has been or will be studied in RCTs in the
near future, this systematic report of the findings and limitations
of all available published studies will be useful, for example, for
informing the design of appropriate RCTs and providing a sum-
mary of all of the evidence on the topic to date.
Types of participants
Inclusion criteria
We have adopted the WHO classification of soft tissue tumors
to define the population of patients with NRSTS (Fletcher 2002)
with the exception of the Ewing family of tumors (see ’Exclusion
criteria’). Studies were included as long as at least 80% of patients
had NRSTS. Children as well as adults were investigated and age
limits did not apply. Participants were included regardless of the
severity of the disease and of clinical staging information, as long as
they received autologous (from either a peripheral or bone marrow
source, or both) HSCT.
Exclusion criteria
Whilst theWHOclassificationofNRSTS includes the Ewing fam-
ily of tumors, that is extraosseous tumor types, we excluded these
because they are primarily bone sarcomas. Because extraosseous
types are rarely diagnosed and share common features, they were
regarded with osseous types as one entity and were excluded.
The clear delineation of soft tissue sarcomas to be included in
the present report and the grounds for exclusion of some tumor
types was hindered by the presence of more than 30 heterogenous
tumor entities, the distinction betweenmalignant tumors and two
categories of intermediate malignancies as described in the WHO
classification (Fletcher 2002), and a complicated histology and
terminology. Therefore, we present the designation of tumors that
were regarded as (malignant) soft tissue sarcomas in the present
review (Table 2) and we present the terms for tumors that were
not considered (Table 3).
Types of interventions
Intervention: autologous hematopoietic stem cell transplantation
(HSCT), stem cells from peripheral source or the bone marrow,
serving as a rescue therapy usually applied after high-dose chemo-
therapy (HDCT).
Comparison: standard-dose chemotherapy, which is defined as
chemotherapy at a lower dose than HDCT without the need for
stem cell rescue.
Allogenic HSCT was excluded.
Types of outcome measures
Primary outcomes
• Overall survival (OS): survival until death, from all causes.
Survival was assessed starting from the time when participants
received autologous HSCT.
• Treatment-related mortality (TRM): deaths that were
classified as treatment related or the participants died of
complications after autologous HSCT.
Secondary outcomes
• Disease-free survival (DFS): time free of disease after
receiving autologous HSCT; the events were death due to all
causes or any sign of the disease. The extent of disease was
evaluated by clinical, histologic and imaging studies.
• Progression-free survival (PFS): time staying free of disease
progression after receiving autologous HSCT. Participants may
still have the disease but their disease is stable or showed a partial
response to treatment; the events are death from all causes or any
progression of the disease.
• Event-free survival (EFS): time staying free of any of a
particular group of defined events after receiving autologous
HSCT. Participants may still have the disease; the events are
death from all causes, any sign of the disease in participants who
had a complete response to treatment, any relapse or progression
of the disease, or events that were defined by the individual study
protocol.
• Failure-free survival (FFS): time staying free of treatment
failure after receiving autologous HSCT; the events are disease-
or treatment-related death, any sign of the disease in participants
who had a complete response to treatment, refractory disease
with no response to treatment, stable disease, or progression of
the disease after treatment.
• Toxicity: adverse events classified according to the common
toxicity criteria (NCI 2009b) within 90 days of autologous
HSCT; grades 3 and 4 of toxicity were extracted and grouped as
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hematological (leukopenia, neutropenia, thrombocytopenia) and
non-hematological (nausea, kidney, liver, nervous system, heart)
toxicities.
• Secondary neoplasia: as classified by the study authors.
• Health-related quality of life (HRQoL): measured using a
questionnaire that has been validated through reporting of
norms in a peer-reviewed publication.
Search methods for identification of studies
The search methods suggested in the Cochrane Handbook for
Systematic Reviews of Interventions (Higgins 2009) and by the
Cochrane Gynaecological Cancer Review Group were used. Arti-
cles in any language were included. Translations were carried out
as necessary.
The literature sources and search steps are shown in Table 4. In
the first step, three different bibliographic databases were searched
electronically to find topic-related articles. In the second step, on-
line registers were searched to find additional information on com-
pleted or ongoing comparative studies that have not been pub-
lished. References cited in 98 identified reviews (Appendix 4), in-
cluding three systematic reviews, were evaluated.
Electronic searches
The following electronic databases were searched: the Cochrane
Central Register of Controlled Trials (CENTRAL) (The Cochrane
Library 2010, Issue 2), Ovid MEDLINE (from 1950 to Febru-
ary 2010), Ovid EMBASE (from 1980 to February 2010). See
Appendix 1, Appendix 2, and Appendix 3 for the appropriate
medical subject headings (MeSH) and text words for the search
strategies. An updated search was run in PubMed (6 June 2010)
using the following terms: (“Transplantation, Autologous”[Mesh]
OR “Peripheral Blood Stem Cell Transplantation”[Mesh]) AND
“Sarcoma”[Mesh].
Searching other resources
Information about trials not listed in CENTRAL, MEDLINE
or EMBASE, either published or unpublished, were located by
searching the reference lists of relevant articles and review arti-
cles. We also electronically searched the abstracts of the confer-
ence proceedings of the American Society of Clinical Oncology
(ASCO) annual meetings (from 2004 to 2009). We searched for
ongoing trials by scanning online registers listed in Table 4. We
also searched for ongoing trials by contacting researchers involved
in the area.
Data collection and analysis
Selection of studies
All titles and abstracts retrieved by electronic searchingwere down-
loaded to the referencemanagement database (ReferenceManager
Version 11) (Thomson Reuters Corp 2009); duplicates were re-
moved and the remaining references were examined by two review
authors (FP and TBH) independently. Those studies which clearly
did not meet the inclusion criteria were excluded and copies of
the full text of potentially relevant references were obtained. The
eligibility of retrieved papers was assessed independently by two
review authors (FP and TBH). Disagreements were resolved by
discussion between the two review authors and consultation with
a third review author (MK), if necessary. Reasons for exclusion
were documented.
Data extraction and management
For included studies, data on characteristics of studies, participants
and interventions; risk of bias; duration of follow up; outcomes
and deviations from protocol were abstracted independently by
two review authors (FP and MaKr). Differences between review
authors were resolved by discussion or by appeal to a third review
author (CB).
Characteristics of studies
• Study type (RCTs, non-RCTs, non-randomised trials with
no control group (phase I or II study), cohort studies, case-
control studies, case series, case reports)
• Design (randomization, sequence generation and
concealment of allocation, blinding, prospective, retrospective,
consecutive enrolment - sample selection)
• Observation period (calendar years)
• Inclusion and exclusion criteria (Ewing family of tumors,
other excluded sarcomas, other solid tumors)
• Number and location of participating centres
Characteristics of participants
• Age
• Gender
• Type of histological category
• Status of metastasis
• Number of recruited and analyzed participants
Characteristics of interventions
• High-dose chemotherapy
• Autologous peripheral blood stem cells
• Autologous bone marrow stem cells
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Survival measures
• Time to event from treatment with HSCT
• Number of events and participants at risk
• Kaplan-Meier survival estimate
• Hazard ratio (HR)
• 95% confidence interval (CI)
• Log rank P value
• Duration of follow up (median; range)
Treatment-related mortality
• Number of events and participants at risk
• Number of recruited and analyzed participants
• Cause of death
Secondary neoplasia
• Number of events and participants at risk
• Number of recruited and analyzed participants
• Type of secondary neoplasia
Toxicity
• Number of WHO grade 3 or 4 adverse events and
participants at risk
• Number of recruited and analyzed participants
• Organ system affected
Quality of life
• Scale
• Number analysed
• Mean or median
• Standard deviation or range
Where relevant and if reported, both unadjusted and adjusted
summary statistics were extracted. Where possible, all data ex-
tracted were those relevant to an intention-to-treat (ITT) analysis
in which participants were analyzed in the groups to which they
were assigned. The time points at which outcomes were collected
and reported were noted.
Assessment of risk of bias in included studies
The assessment of risks of bias in included controlled studies was
independently applied at the study level by two review authors
(FP and MaKr) according to Table 5 and to the guidelines of
the Cochrane Handbook for Systematic Reviews of Interventions
(Higgins 2009). Differences were resolved by discussion or by
appeal to a third review author (CB). Results of data syntheses
were interpreted in light of the findings with respect to risk of bias.
Assessment of blinding of the care provider and blinding of the
participants was not applicable as blinding is not ethically accepted
for studies on stem cell transplantation.
Measures of treatment effect
We used the following measures of the effect of treatment.
• For time to event data we used the HR, if possible.
• For dichotomous outcomes we used the risk ratio (RR) or
odds ratio (OR).
• For continuous outcomes we used the mean difference
between treatment arms on the condition that the distribution
characteristics had been evaluated.
Studies reporting aggregate data that combined the results of sev-
eral participants (including results from separately reported sub-
populations that fulfilled the inclusion criteria) were distinguished
from studies with individual data of single participants. Data from
these studies were described as narrative summaries.
In some studies diagnoses of NRSTS were mixed with non-
NRSTS solid tumors and rhabdomyosarcomas to such an extent
that the proportion of NRSTS participants was less than 80% of
the study population. In this case, if data on single participants
were identified that fulfilled the inclusion criteria of the present
review we included the study and data for the individual partici-
pant in data analysis.
Estimates of OS were considered for the evaluation if the use of
the Kaplan-Meier method was reported in the study. A survival
analysiswas conducted of individual participant level data based on
theKaplan-Meiermethod.Datawere not used for survival analysis
if the follow-up data were only available for selected participants
and if the beginning of the follow-up period was not reported
clearly, or reported as starting from the time of diagnosis. Statistical
analyses of time to event data were performed using SAS Version
9.2 (SAS Institute Corp 2009).
Unit of analysis issues
None
Dealing with missing data
Information on the outcome status and on the follow-up period
had to be complete for all participants in each study. We did not
impute missing outcome data for the primary outcome. If data
were missing or only imputed data were reported we contacted
trial authors to request data on the outcomes among participants
who were assessed.
Assessment of heterogeneity
The data were entered in Review Manager Version 5 (Review
Manager 2008) and analyzed according to the guidelines of the
Cochrane Handbook for Systematic Reviews of Interventions (
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Higgins 2009). We looked for sources of clinical heterogeneity
due to differences in:
• risk factors of participants studied, i.e. tumor subdiagnosis
or histology, presence or absence of metastasis;
• study design; and
• likelihood of bias.
Heterogeneity between studies was assessed by inspection of the
study methods and participants’ characteristics. Forest plots and
formal statistical tests could not be conducted because the body of
studies did not contain sufficient numbers of comparative studies.
Data synthesis
Aggregate data reported in controlled studies or case series were
synthesized narratively. In contrast, individual data were pooled
and available time-to-event data were analyzed in a Kaplan Meier
survival analysis.
Subgroup analysis and investigation of heterogeneity
No subgroup analyses were carried out.
Sensitivity analysis
No sensitivity analyses were carried out.
R E S U L T S
Description of studies
See:Characteristics of included studies; Characteristics of excluded
studies.
Results of the search
Considering all sources as shown in Table 4, 4784 different articles
(duplicates removed) were identified (Figure 1). The titles and
abstracts of 4317 articles did not fulfil the inclusion criteria and
10% (467 of 4784) of the retrieved articles were evaluated in detail
using the full text. Of these a total of 11% (54 of 467 references)
of the full text articles were included in the present review and the
other 413 studies were excluded.
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Figure 1. Literature search and study flow. Abbreviations: EBMT STWP: European Group for Blood and
Marrow Transplantation Soft Tissue Working Party; HDCT: high-dose chemotherapy; HSCT: hematopoietic
stem cell transplantation; N: number; NCI PDQ: National Cancer Institute Physician Data Query Clinical
Trials; NIHR UKCRN: National Institute for Health Research (NIHR) UK Clinical Research Network’s Portfolio
Database; NRSTS: non-rhabdomyosarcoma soft tissue sarcoma; RMS: rhabdomyosarcoma; STS: soft tissue
sarcoma. WHO ICTRP: World Health Organization International Clinical Trials Registry Platform.
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We were unable to identify any additional studies from screening
the reference lists of included studies and reviews or from institu-
tions and authors. Relevant studies were not identified from on-
line trial registries or congress proceedings, described in Table 4,
either.
Included studies
We identified 54 studies including a total of 246 participants: 177
that received HDCT followed by autologous HSCT transplant
and 69 that received standard therapy. The characteristics of all
54 included studies are described in the section Characteristics of
included studies.
We included one retrospective study in which 34 participants who
received HDCT followed by autologous HSCT were compared
with a historical control group consisting of 69 participants with
STS matched for age, gender, histological diagnosis and stage of
disease and who received standard care (Ivanova 2007). This study
did not provide sufficient detailed information about the control
group to allow a meaningful evaluation. One study had a prospec-
tive design and included 10 participants with NRSTS who re-
ceived HDCT and peripheral HSCT (Bertuzzi 2003). The re-
maining 52 studies comprised 16 phase I or II prospective trials
with no control groups and 36 retrospective case series or indi-
vidual case reports. Whilst not all participants had NRSTS in the
studies that were phase I or II prospective trials, data were reported
for individual participants so that we were able to include these
studies. RCTs and clinical controlled studies with a concurrent
control group were not identified.
Excluded studies
A total of 88% (413 of 467 references) of the potentially relevant
articles were excluded (Figure 1) based on:
• diagnosis not STS according to Table 2 (n = 55);
• not NRSTS (individual data) or less than 80% NRSTS
(aggregate data) (n = 53);
• intervention not autologous HSCT (n = 89);
• primary outcome survival not reported (n = 91);
• study design was a review, editorial, abstract (n = 111);
• duplicate publication (n = 10);
• congress abstract (n = 4).
Excluded studies are described in the Characteristics of excluded
studies table.
Risk of bias in included studies
Comparative studies
The design of the study by Ivanova 2007 was not clearly reported;
we categorised it as a retrospective comparative study that used
historical data to create a control group. Results of 34 participants
that receivedHSCTwere compared to 69 participants that did not
receive HSCT. The author reported that the groups were matched
for age, gender, histology and stage, though we were unable to
verify this as insufficient data were reported in the article. Assign-
ment to treatment groups was not described, the participant flow
was unclear and loss to follow up was not addressed. Selective
outcome reporting was unclear in this retrospective study, study
results were reported amidst reports of results from other studies
and information about statistical methods was sparse. Therefore,
the risk of bias was very large. Data for individual participants
were not reported.
Non-comparative studies
The risk of bias was high in all 53 studies due to the study design
being either phase I and II non-comparative trials, case reports or
case series.
Aggregate data
In one study (Bertuzzi 2003) the characteristics of the participants
and the intervention were described in detail and the participants
were described as a consecutive sample. The primary outcome,
OS, was clearly reported in the text and shown in an appropriate
graph; the Kaplan-Meier method was used to conduct a survival
analysis. All 10 included participants had the histologic subtype
of desmoplastic small round-cell tumor. The prognosis of this
subtype may be regarded as specific and not comparable to other
subtypes. Data for individual participants were not reported.
Individual participant data
In 52 studies, the characteristics of the participants and the in-
tervention were described in detail. The primary outcome of OS
was clearly reported in the text or tables, however the start of the
follow-up period varied between the studies and was not reported
in every study. We defined the start of the follow up as the time of
treatment, either transplantation or high-dose chemotherapy. The
start of follow up as the time of diagnosis was not accepted because
the time lag between diagnosis and intervention can be consid-
erable, as demonstrated in a study on 22 participants with STS
including 11 NRSTS and 11 RMS: “Median delay between diag-
nosis and intensification was between 4 to 39months” (Dumontet
1992). Therefore, OS with treatment was estimated using only
data with complete outcome and follow-up information for the
pooled analysis. Considerable data were incomplete or inappro-
priate, resulting in 59% (79 of 133 participants) of the pooled
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individual data being excluded from the analysis, therefore only
41% (54 of 133 participants in 29 studies) of the data were used
in the pooled survival analysis.
Allocation
The allocation of participants to the two alternative treatment
groups was not described in the one comparative study.
Blinding
Blinding was not assessed as it is unlikely that blinding of par-
ticipants or investigators would be adopted in studies evaluating
HSCT.
Incomplete outcome data
There was insufficient reporting of attrition and exclusions to per-
mit judgement whether incomplete outcome data were adequately
addressed. Participant flow, prospective comparative study design,
characteristics of both treatment groups and outcomes were not
described in detail. Consecutive recruitment of participants was
described in the one case serieswith aggregate data (Bertuzzi 2003).
Selective reporting
There was insufficient information to permit judgement of
whether the reports were free of selective outcome reporting. It
is likely that all studies fall into this category. The start of follow
up was not stated in one (Ivanova 2007) of two studies that pre-
sented aggregate outcome data. Follow-up data were not reported
adequately for 59% (79 of 133) of participants of studies that pre-
sented individual data, therefore we could not use the data. TRM
was not addressed in every study. Secondary neoplasia is a long-
term outcome that was not addressed in every study. Data on tox-
icity outcomes could not be extracted from most studies because
they were not reported individually for the population of interest.
Other potential sources of bias
All 54 studies had a potential source of bias related to the specific
study design used, such as lack of a control group or no description
of the characteristics of a control group, no reporting of how the
participants were selected and no reporting of reasons for loss to
follow up.
Effects of interventions
Overall survival (OS)
In one comparative study (Ivanova 2007), OS at two years after
HSCT was estimated as 62.3% when compared with 23.2% for
participants that received standard care. The difference was re-
ported to be statistically significant (Table 6) although the statis-
tical test was not described and a P value was not reported. The
Kaplan-Meier estimator for OS at two years after transplantation
was reported as 20% in another study (Bertuzzi 2003) with ag-
gregate data of 10 participants with desmoplastic small round-cell
tumors (Table 6). In the pooled survival analysis of 54 individuals
who received HSCT, OS at two years was estimated as 49% (95%
CI 34% to 64%) (Table 6; Figure 2).
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Figure 2. Meta-analysis of overall survival of 54 individual patients with complete follow-up information
pooled from 29 case series and case reports. Number of patients at risk at 1 year intervals. Abbreviations:
HDCT: high-dose chemotherapy; HSCT: hematopoietic stem cell transplantation; NRSTS: non-
rhabdomyosarcoma soft tissue sarcoma.
Treatment-related mortality (TRM)
TRM was addressed in eight non-comparative studies (67 trans-
planted participants) and a procedure-related death was described
for 11 participants (Table 7). Severe infection was the main cause
of death (4 cases). TRMwas not addressed in the study by Ivanova
2007.
Disease-free survival
Not reported
Progression-free survival (PFS)
PFS at two years after transplantation was reported as 0% in one
study (Bertuzzi 2003) with aggregate data of participants with
desmoplastic small round-cell tumors (Table 6).
Event-free survival
Not reported
Failure-free survival
Not reported
Secondary neoplasia
Secondary neoplasia was addressed in one case report (Table 8)
and was not addressed in the comparative study (Ivanova 2007).
Toxicity
Data on hematological and non-hematological severe toxicity
grade 3 to 4 (NCI CTEP 2006) after transplantation was sparse
and extracted from five non-comparative studies only (Table 9).
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Subgroup analysis
Subgroup analyses were not conducted.
Health-related quality of life
Studies on health-related quality of life were not identified.
D I S C U S S I O N
Summary of main results
We identified only one comparative study, with a high likelihood
of bias. OS at two years for participants in the HSCT group was
significantly higher than for participants in the control group. In
one case series of 10 participants with desmoplastic small round-
cell tumors, OS at two years was low at 20%, which may reflect
that participants with this special tumor type have a lower risk of
survival than participants with other NRSTS. Our estimated OS
of 49%at two years for the remaining studies with participant level
data falls within the range reported above for the two studies with
aggregate data. For TRM even the more conservative estimate,
6.2%, is considerably higher than the 2.0% TRM within the first
days following HSCT reported by the EBMT registry (EBMT
2009) for the year 1998 (Rosti 2002). Secondary neoplasia was
reported for 0.6% of participants and was probably an extreme
underestimation of the true frequency because of relatively short
follow up in the included studies and the fact that the included
studies were not designed to specifically detect secondary neopla-
sia. The detection of secondary neoplasia depends on a long follow
up, which might be provided by cancer registers. This reported
incidence compares with a frequency of 4.0% for secondary neo-
plasia based on register data (Neglia 2001) and 6.9% (Baker 2003)
after a long observation period of 20 years. Severe toxicity grade 3
to 4 was sparsely reported.
Overall completeness and applicability of
evidence
Many of the studies we identified had to be excluded because they
included participants with a mixture of heterogenous tumors and
the proportion of participants with NRSTS was fewer than 80%.
Furthermore, most treatments were performed 10 to 20 years ago.
Thus, the results may not be applicable to patients who are treated
today. It is also a possibility that the results reflect the course of
the disease and an effect of the prior therapy rather than the effect
of the test intervention.
Quality of the evidence
All 54 studies have a high risk of bias. The one comparative study
lacks information on the characteristics of participants, the inter-
vention and applied statistical methods. Thus, these data do not
provide any evidence that HDCT followed by autologous HSCT
has additional benefit over standard therapy. An additional de-
scriptive analysis of 52 phase I and II studies, case series or case re-
ports showed that there are many different tumor types of NRSTS
treated by transplantation, though each individual NRSTS entity
was scarce. We found that a pooled survival analysis of individ-
ual participant data from phase I and II studies and case reports
was considerably hampered. Specifically, the majority of required
follow-up information was incomplete or missing and, therefore,
could not be included in the survival analysis. One requirement
for survival analysis is a unique definition of the start of the fol-
low-up period for all included participants. This was missing from
many studies. As suggested by the low OS for desmoplastic small
round-cell tumor, each entity may carry an individual risk profile
and, therefore, ideally should be evaluated separately. The body
of evidence does not allow robust conclusions in relation to the
objectives of the review.
Potential biases in the review process
Strengths
The search strategywas broad and it is likely that all relevant studies
were identified. The WHO classification of NRSTS was adopted
and modified to define a clear terminology for the study selection
process. Studies were excluded if the proportion of non-eligible
participants were greater or equal to 20% of the total population.
The follow up of participants with individual data had to begin
at the same time point to be considered in the pooled analysis of
survival. Authors were contacted to ask for additional data.
Limitations
RCTs and non-controlled trials with low risk of bias were not iden-
tified and only one comparative study with high risk of bias was
identified. No database is available for a conclusive comparison.
Many studies were excluded because participants with NRSTS
were includedwith participantswith othermalignant diseases. The
heterogeneity of NRSTS and the possible different terminology
used in publications may have led us to overlook studies with eli-
gible participants. This may be more an issue for case series but it
is highly unlikely for controlled trials. The pooled survival analysis
of individual data was based on less than half of all the individual
data available and the exclusion of these data whilst intending to
reduce bias may also have introduced bias.
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Agreements and disagreements with other
studies or reviews
In the last two decades, from 1986 to 2007, the lack of evidence
and need to conduct randomized controlled trials was stated in
at least 20 publications (Blay 2000; Carvajal 2005; Dumontet
1992; Ek 2006; Elias 1998; Hale 2005; Kasper 2004; Kasper
2007; Kavan 1997; Ladenstein 1997;Mackall 2001;Meyers 2004;
Michon 1999; Pinkerton 1986; Reichardt 2002; Rosti 2002;
Schlemmer 2006; Seeger 1991; Weigel 2001; Woods 1999) seek-
ing to clarify the relevance of HDCT followed by autologous
HSCT inhigh-risk patientswith STS.We identified reviews onOS
at five years after chemotherapy without transplantation. The esti-
mates were 6% (Ramanathan 1999), less than 10% (Banna 2007;
Van Glabbeke 1999), 14% (Tumorregister München 2007) and
10% to 20% (Clark 2005). In the control group of Ivanova 2007,
OS at two years was 23%. A systematic review (Verma 2008) was
performed to determine whether first-line dose-intensive chemo-
therapy supported by growth factor or autologous bone marrow
or stem cell transplantation improves outcomes compared with
standard-dose chemotherapy in patients with inoperable, locally
advanced or metastatic soft tissue sarcoma. In this review, only
one case series (Schlemmer 2006) with HDCT followed by autol-
ogous HSCT was reported, which was excluded from the present
review. In a narrative review (Banna 2007) of HDCT followed by
autologous HSCT in patients with solid tumors, outcomes were
reported for three sarcomas (rhabdomyosarcoma, Ewing sarcoma
and osteosarcoma) not included in the present review. Predictive
values were not reported in a review (Clark 2005) on soft tissue
sarcomas in adults. Kasper 2005 concluded that the use of HDCT
for locally advanced or metastatic adult (soft tissue and bone) sar-
comas still remains highly investigational and should not be per-
formed outside clinical trials.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
The evidence base does not support the use of HDCT followed
by autologous HSCT in high-risk patients with NRSTS except in
prospective concurrent, preferably randomized, controlled trials.
Implications for research
Randomized controlled trials are needed to clarify the relevance of
HDCT followed by autologous HSCT in patients with NRSTS.
If non-randomized controlled studies are conducted, a low risk
of bias should be achieved. Case series and case reports are not
helpful. Criteria of included tumor types should adhere to the
WHO classification.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Al Balushi 2009
Methods Retrospective report of cases without control in a single-centre, observed in Canada from 2000 to 2007
Participants 5 children with desmoplastic small round-cell tumor with metasteses; 4 male, 1 female; mean age 11 years
Interventions HDCT followed by autologous HSCT in 3 of 5 children
Outcomes overall survival; toxicity
Notes individual data for each child presented
Andres 2006
Methods Retrospective report of a single case without control in a single-centre, observed in Spain; no information on obser-
vation period available
Participants 1 female 21 years of age with desmoplastic small round-cell tumor
Interventions HDCT followed by autologous HSCT
Outcomes overall survival; toxicity
Notes
Bernbeck 2007
Methods Retrospective report of cases without control in a single-centre study, observed in Germany from 2001 to 2005
Participants 9 participants with high-risk soft tissue sarcomas, 8 of whom had rhabdomyosarcoma or synovial sarcoma at various
clinical stages. Children and young adults (3 male, 5 female) ranging from 1 to 21 years of age
Interventions HDCT followed by autologous peripheral HSCT
Outcomes survival; toxicity
Notes individual data for each participant presented
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Bertuzzi 2003
Methods Prospective study of consecutive cases without control in a single-centre, observed in Italy from 1997 to 2002
Participants 10 adults (10 male) aged 15 to 60 years, median 29 years of age with advanced desmoplastic small round-cell tumor
at various clinical stages, n=4 with metastases
Interventions HDCT (melphalan, mitoxantrone, thiotepa) followed by autologous peripheral HSCT
Outcomes overall survival; progression-free survival; toxicity (NCI-CTC)
Notes aggregate data
Bley 2004
Methods Retrospective report of a single case without control in a single-centre, observed in Germany; no information on
observation period available
Participants 1 female 22 years of age with liposarcoma
Interventions HDCT followed by autologous HSCT
Outcomes overall survival; toxicity
Notes
Bölke 2005
Methods Retrospective report of a single case without control in a single-centre, observed in Germany in 1993
Participants 1 female 33 years of age with recurrent malignant fibrous histiocytoma
Interventions HDCT followed by autologous peripheral HSCT
Outcomes overall survival; adverse events
Notes
Cole 1999
Methods Retrospective report of a single case without control in a single-centre, observed in the United States; information
on observation period not available
Participants 1 male 26 years of age with synovial sarcoma
Interventions HDCT followed by autologous peripheral HSCT
Outcomes overall survival; adverse events
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Cole 1999 (Continued)
Notes
Doros 2008
Methods Retrospective report of a single case without control in a single-centre, observed in the United States; information
on observation period not available
Participants 1 male 14 years of age with desmoplastic small round-cell tumor
Interventions HDCT followed by autologous HSCT
Outcomes overall survival; adverse events
Notes
Endo 1996
Methods Retrospective report of a case series without controls in a single-centre, observed in Japan from 1987 to 1995
Participants 16 participants with high-risk solid tumors; of which 1 male 19 years of age with undifferentiated sarcoma
Interventions HDCT followed by autologous peripheral and bone marrow HSCT
Outcomes overall survival; adverse events
Notes individual data available for each case
Engelhardt 2007
Methods Retrospective report of a consecutive series of cases without control, observed from 1992 to 2003; the number of
centres and the countries were not specified (probably in Germany and the United States of America)
Participants 35 participants with Ewing sarcoma and soft tissue sarcomas, of which 23 had NRSTS (anaplastic soft tissue sar-
coma, angiosarcoma, fibrosarcoma, leiomyosarcoma, liposarcoma, malignant fibrous histiocytoma, malignant hae-
mangioperiocytoma, synovial sarcoma); 12 male, 11 female, 21 to 56 years of age
Interventions HDCT followed by autologous peripheral HSCT
Outcomes survival; toxicity
Notes individual data for participants with rhabdomyosarcoma and other soft tissue sarcoma. The reported aggregate data
were not considered because the proportion of participants with NRSTS plus 3 rhabdomyosarcomas was less then
80% of all participants therefore did not meet our eligibility criteria
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Fang 2008
Methods Retrospective report of cases without control in a single-centre, observed in the United States in 2006
Participants 2 cases, 1 of whom had a desmoplastic small round-cell tumor; female 23 years of age
Interventions HDCT followed by autologous peripheral HSCT
Outcomes survival
Notes individual data presented for each participant
Farruggia 2008
Methods Retrospective report of a single case in a single-centre, observed in Italy; information on observation period not
available
Participants 1 male 10 years of age with synovial sarcoma
Interventions HDCT followed by autologous peripheral HSCT
Outcomes overall survival; toxicity
Notes
Fetscher 1997
Methods Retrospective report of a single case in a single-centre, observed in Germany in 1994
Participants 1 female 23 years of age with metastatic leiomyosarcoma
Interventions HDCT followed by autologous peripheral HSCT
Outcomes overall survival
Notes
Frapier 1998
Methods Retrospective report of a single case in a single-centre, observed in France; information on observation period not
available
Participants 1 male 11 years of age with high grade undifferentiated sarcoma
Interventions HDCT followed by autologous bone marrow HSCT
Outcomes survival; adverse events
44Autologous hematopoietic stem cell transplantation following high-dose chemotherapy for non-rhabdomyosarcoma soft tissue sarcomas
(Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Frapier 1998 (Continued)
Notes
Fraser 2006
Methods Report of two prospective phase I/II studies of cases without control in a single-centre, observed in the United States
from 1995 to 2004
Participants 36 participants with solid tumors that were metastatic or relapsed following therapy, treated on two consecutive trial
protocols n=11 and n=25; 5 had desmoplastic small round-cell tumor and rhabdoid tumor; aged from 2 to 20 years
Interventions HDCT followed by autologous peripheral or bone marrow HSCT
Outcomes survival; toxicity
Notes individual data for each participant reported on
Garrido 1998
Methods Retrospective report of cases in a single centre; observed in the United States; 1991 to 1995
Participants 2 participants, n=1 45 year old man with metastatic liposarcoma
Interventions HDCT followed by autologous HSCT
Outcomes adverse events
Notes individual data available for each case
Graham 1997
Methods Prospective phase I/II trial in a single centre, observed in the United States from 1991 to 1995
Participants 49 participants with recurrent and high-risk pediatric brain tumors 1 of whom had fibrosarcoma; aged 1 to 32 years,
median 12 years
Interventions HDCT followed by autologous bone marrow HSCT
Outcomes survival; toxicity
Notes individual data available for participants
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Hawkins 2002
Methods Prospective phase I/II trial without controls in a 3-centre study, observed in United States from 1996 to 1998
Participants 23 children and adolescents with metastatic sarcomas of whom 6 had NRSTS (desmoplastic small round-cell tumor,
fibromyxoid sarcoma, leiomyosarcoma, undifferentiated sarcoma) 5 male; 1 female, ranging from 5 to 19 years of
age
Interventions HDCT followed by autologous peripheral HSCT
Outcomes survival, toxicity
Notes individual data available for each participant
Hoogerbrugge 1997
Methods Retrospective report of a single case in a single centre, observed in the Netherlands; information on observation
period not available
Participants 1 child 1 year of age with fibrosarcoma; information on gender not available
Interventions HDCT followed by autologous bone marrow HSCT
Outcomes overall survival; toxicity
Notes
Ivanova 2007
Methods Retrospective report of cases with results from a control group in a single-centre study,
observed in Russia from 1990 to 2006
Participants 103 patients with various soft tissue sarcomas were investigated in two treatment groups;
individual information on diagnoses, age and gender not available
Interventions 34 children were treated with HDCT (carboplatin, cyclophosphamide, etoposide) fol-
lowed by autologous HSCT; 69 children as a control; information on the control therapy
not available
Outcomes overall survival, adverse events
Notes aggregate data
Risk of bias
Bias Authors’ judgement Support for judgement
Assignment of patients to treatment groups High risk no information about assignment; study
report results about transplanted patients
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Ivanova 2007 (Continued)
such as a case series; then adds OS of an un-
specified control group; control group was
matched to the test group, however, the de-
scription of this procedure was not com-
prehensible
Concurrent control High risk control group was probably selected from
historical data
Comparable baseline characteristics Unclear risk no report about patients’ characteristics, ex-
cept the average tumor volume 180 cm3
which was comparable in both groups; no
other baseline characteristics; information
insufficient to assess comparability between
groups
Loss to follow-up Unclear risk loss to follow up was not addressed; no pa-
tient flow described
Selective outcome reporting Unclear risk the study has a retrospective design and a
study protocol is not available
Other causes for high risk of bias Unclear risk study results were reported amidst reports
of results from other studies; the article
resembles a narrative review; information
about statistical methods was sparse
Kaminski 2000
Methods Retrospective report of a single case in a single centre, observed in the United States in 1993
Participants 1 child (female) 6 years of age with fibrosarcoma
Interventions HDCT followed by autologous bone marrow HSCT
Outcomes overall survival; adverse events
Notes
Kasper 2007
Methods Retrospective report of cases without control in a single-centre study, observed in Germany from 1998 to 2007
Participants 38 participants with soft tissue and bone sarcomas, of whom 14 had NRSTS (leiomyosarcoma; liposarcoma; malig-
nant fibrous histiocytoma; not otherwise specified soft tissue sarcomas; synovial sarcoma) aged 23 to 65 years; no
individivual information available on gender
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Interventions HDCT followed by autologous peripheral HSCT
Outcomes toxicity (WHO)
Notes mainly aggregate data reported
Kasper 2010
Methods Prospective controlled clinical trial; single-institutional phase II study, observed in Ger-
many from 2003 to 2008
Participants 34 patients with various solid tumors were investigated in two treatment groups
Interventions 9 participants with solid tumors were treated with HDCT (ifosfamide, carboplatin,
etoposide) followed by autologous HSCT (peripheral blood stem cell rescue), of whom 7
had NRSTS (leiomyosarcoma; malignant fibrous histiocytoma; not otherwise specified
soft tissue sarcomas; synovial sarcoma); aged 29 to 65 years of age
25 participants with solid tumors were treated in a control group with standard-dose
chemotherapy (ifosfamide, doxorubicin), of whom 20 had NRSTS (leiomyosarcoma;
liposarcoma;malignant fibrous histiocytoma; not otherwise specified soft tissue sarcomas;
synovial sarcoma); age was not reported
Outcomes overall survival; progression-free survival; adverse events
Notes aggregate data included less than 80% NRSTS patient data; individual data for trans-
planted data were available but not included in the meta-analysis because follow up did
not start at intervention
Risk of bias
Bias Authors’ judgement Support for judgement
Assignment of patients to treatment groups High risk no information about assignment; all par-
ticipants had metastatic disease; study re-
ports results about transplanted and con-
trol patients such as a case series
Concurrent control Low risk all participants were treated bewteen 2003
and 2008
Comparable baseline characteristics Unclear risk tumor classification and metastatic site re-
ported for all participants; age reported
for 9 transplanted participants; no other
baseline characteristics; information insuf-
ficient to assess comparability between
groups
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Loss to follow-up Unclear risk loss to follow up was not addressed; no pa-
tient flow described
Selective outcome reporting Unclear risk overall survival was assessed from time of
study inclusion and not from time of trans-
plantation; the gap between study inclu-
sion and transplantation may be up to
4 months; reporting makes comparision
to other studies difficult; treatment-related
mortality not reported; toxicity reported
scarcely
Other causes for high risk of bias Unclear risk duplicate data because some patients were
reported in Kasper 2007 and Kasper 2010
Kozuka 2002
Methods Retrospective report of cases without control in a single-centre study, observed in Japan from 1999 to 2000
Participants 2 adults (2 male) 21 and 37 years of age with recurrent NRSTS (malignant fibrous histiocytoma or malignant
hemangiopericytoma)
Interventions HDCT followed by autologous peripheral HSCT
Outcomes survival; adverse events
Notes individual data for each participant reported
Kretschmar 1996
Methods Retrospective report of cases in a single-centre study, observed in the United States; information on observation
period not available
Participants 3 adolescent males with desmoplastic small round-cell tumor, 1 of whom received HSCT (13 years of age)
Interventions HDCT followed by autologous bone marrow HSCT
Outcomes survival; toxicity
Notes
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Krskova 2007
Methods Retrospective report of a single case in a single centre, observed in the Czech Republic in 1998
Participants 1 child (male) 9 years of age with synovial sarcoma
Interventions HDCT followed by autologous HSCT
Outcomes overall survival; adverse events
Notes
Kurre 2000
Methods Retrospective report of 3 cases in a single-centre study, observed in the United States from 1994 to 1998
Participants 3 cases with desmoplastic small round-cell tumor, 2 of whom received HSCT: 1 male aged 5 years and 1 female aged
2.5 years
Interventions HDCT followed by autologous peripheral HSCT
Outcomes survival; adverse events
Notes individual data reported for each participant
Kushner 1996
Methods Prospective phase I/II study without controls in a single centre, observed in the United States; information on
observation period not available
Participants 12 patients with desmoplastic small round-cell tumor of whom 4 boys from 10 to 14 years of age received HSCT
Interventions HDCT (P6 protocol) followed by autologous bone marrow HSCT
Outcomes Survival; toxicity (NCI CTC criteria)
Notes individual data reported for each participant
Kushner 2001
Methods Preliminary results from a prospective phase II/III study in a single-centre study, observed in the United States;
information on observation period not available
Participants 21 participants with neuroblastoma, brain tumors and other poor-risk solid tumors, of whom 1 male 29 years of age
with desmoplastic small round-cell tumor
Interventions HDCT followed by autologous peripheral HSCT
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Outcomes overall survival; toxicity according to NCI CTC criteria
Notes individual data for each participant available
Kushner 2008
Methods Retrospective report of a case in a single-centre study, observed in the United States; information on observation
period not available
Participants 1 adult (male) 18 years of age with desmoplastic small round-cell tumor
Interventions HDCT followed by autologous peripheral HSCT
Outcomes survival; adverse events
Notes individual data
Kühne 2000
Methods Prospective phase I/II study without control group in a single centre, observed in Switzerland from 1997 to 1999
Participants 11 children with brain tumors, soft tissue sarcomas, germ-cell tumors and neuroblastomas, of whom 1 child (male)
3 years of age with rhabdoid sarcoma
Interventions HDCT followed by autologous peripheral HSCT
Outcomes overall survival; adverse events
Notes individual data available for each participant
Lafay-Cousin 2000
Methods Prospective phase II study without controls in a 4-centre study, observed in France from 1986 to 1998
Participants 18 children with recurrent mesenchymal tumors, of whom 4 (2 male; 2 female) from 10 to 16 years of age with
NRSTS (desmoplastic small round-cell tumor; undifferentiated sarcoma)
Interventions HDCT followed by autologous peripheral or bone marrow HSCT
Outcomes overall survival; adverse events
Notes individual data reported for each participant
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Lashkari 2009
Methods Prospective phase II study without controls in a single centre, observed in the USA from 1995 to 1999
Participants 13 children with locally advanced or metastatic sarcoma; of whom 2 (1 male; 1 female) 40 and 30 years of age with
metastatic NRSTS (malignant fibrous histiocytoma; soft tissue sarcoma without histologic subtype information)
Interventions HDCT followed by autologous HSCT
Outcomes survival
Notes individual data reported for each participant
Lippe 2003
Methods Retrospective report of 2 cases without controls in a single-centre study; information on observation period not
available
Participants Two participants with desmoplastic small round-cell tumor; of whom 1 adult (male) 27 years of age received HSCT
Interventions HDCT followed by autologous HSCT
Outcomes survival; toxicity
Notes individual data reported for each participant
Livaditi 2006
Methods Retrospective report of 5 cases without controls in a single centre, observed in Greece; information on observation
period not available
Participants 5 children with desmoplastic small round-cell tumor, of whom 2 (1 male aged 7 years and 1 female aged 13 years)
received HSCT
Interventions HDCT followed by autologous peripheral HSCT
Outcomes survival; adverse events
Notes individual data reported for each participant
Madigan 2007
Methods Retrospective report of 14 cases without controls in a single centre, observed in the United States from 1983 to 2003
Participants 14 children with extracranial rhabdoid tumors, of whom 2 (1 male aged 6 months and 1 female aged 30 months)
received HSCT for rhabdoid sarcoma
Interventions HDCT followed by autologous HSCT
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Madigan 2007 (Continued)
Outcomes survival; adverse events
Notes some individual data reported for each participant and aggregate data on survival time in Kaplan-Meier curve
Matsuzaki 2002
Methods Retrospective report of a single case in a single centre, observed in Japan in 1999
Participants 1 child (female) 11 years of age with synovial sarcoma
Interventions HDCT followed by autologous peripheral HSCT
Outcomes overall survival; adverse events
Notes individual data
Mazuryk 1998
Methods Retrospective report of a single case in a single centre, observed in Canada in 1996
Participants 1 female 19 years of age with desmoplastic small round-cell tumor
Interventions HDCT followed by autologous HSCT
Outcomes overall survival; adverse events
Notes
Mesia 1994
Methods Retrospective report of a series of cases without controls in a single centre, observed in Spain from 1989 to 1992
Participants 9 patients with metastatic sarcomas, of whom 1 male 21 years of age had undifferentiated sarcoma
Interventions HDCT followed by autologous bone marrow HSCT
Outcomes survival; adverse events
Notes individual data reported for individual patients
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Mitchell 1994
Methods Unclear if retrospective or prospective study without controls in a single centre, observed in the United Kingdom;
information on observation period not available
Participants 11 patients with malignant disease, of whom 1 male 16 years of age with angiosarcoma
Interventions HDCT followed by autologous peripheral and bone marrow HSCT
Outcomes survival; toxicity
Notes individual data reported for each participant
Nakamura 2008
Methods Retrospective report of a case without control in a single-centre study, observed in Japan; information on observation
period not available
Participants 1 child (male) 11 years of age with undifferentiated soft tissue sarcoma
Interventions HDCT followed by autologous HSCT
Outcomes overall survival; adverse events
Notes
Navid 2006
Methods Prospective phase II study without controls in a single centre, observed in the United States from 1996 to 2000
Participants 24 patients with high-risk sarcomas, of whom 4 had desmoplastic small round-cell tumor and 2 received HSCT(2
males aged 14 and 21 years)
Interventions HDCT followed by autologous peripheral and bone marrow HSCT
Outcomes survival; adverse events
Notes individual data reported for each participant
Patel 2004
Methods Prospective phase II study without controls in a single-centre, observed in the United States from 1994 to 2001
Participants 37 patients with skeletal osteosarcoma and variant bone tumors with poor prognosis, of whom 6 adults hadmalignant
fibrous histiocytoma; individual information on age and gender not available, median age 38 years, range 18-63 years
Interventions HDCT followed by autologous peripheral HSCT
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Patel 2004 (Continued)
Outcomes toxicity according to NCI CTC
Notes individual data available for toxicity
Peters 1986
Methods Prospective phase I studywithout controls in a single centre, observed in theUnited States; information on observation
period not available
Participants 29 patients with metastatic cancer and sarcoma, of whom 2 females aged 24 and 38 years of age with fibrosarcoma
and leiomyosarcoma
Interventions HDCT followed by autologous bone marrow HSCT
Outcomes overall survival; toxicity
Notes individual data reported for each participant
Peters 1989
Methods Prospective phase I studywithout controls in a single centre, observed in theUnited States; information on observation
period not available
Participants 23 patients with metastatic cancer and sarcoma, of whom 2 patients aged 15 and 26 years with synovia sarcoma;
individual information on gender not available
Interventions HDCT followed by autologous bone marrow HSCT
Outcomes adverse events
Notes individual data
Recchia 2006
Methods Retrospective report of a single case in a single centre, observed in Italy; information on observation period not
available
Participants 1 adult (male) 40 years of age with malignant fibrous histiocytoma
Interventions HDCT followed by autologous peripheral HSCT
Outcomes overall survival; toxicity
Notes individual data
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Ronghe 2004
Methods Retrospective report of 2 cases in a single centre, observed in the United Kingdom; information on observation period
not available
Participants 2 children with malignant rhabdoid tumors, of whom 1 female 14 months of age received HSCT
Interventions HDCT followed by autologous bone marrow HSCT
Outcomes overall survival; adverse events
Notes individual data reported for each patient
Saab 2007
Methods Retrospective report of cases in a single centre, observed in the United States; information on observation period not
available
Participants 11 participants with desmoplastic small round-cell tumor, of whom 4males from 5 to 21 years of age received HSCT
Interventions HDCT followed by autologous HSCT
Outcomes survival; toxicity
Notes individual data reported for each participant
Shaw 1996
Methods Prospective phase I study without controls in Australia, UK and Israel; information on the number of centres not
available
Participants 30 patients with malignant solid tumors, of whom 2 children aged 1 and 2 years with NRSTS (rhabdoid sarcoma;
not otherwise specified); individual information, gender not available
Interventions HDCT followed by autologous peripheral or bone marrow HSCT
Outcomes adverse events
Notes individual data for each participant reported
Slease 1988
Methods Phase I trial in a single-centre study, observed in the United States; information on observation period not available
Participants 26 adults with refractory malignant solid tumors, of whom 3 adult males from 41 to 47 years of age with NRSTS
(leiomyosarcoma; malignant fibrous histiocytoma)
Interventions HDCT followed by autologous bone marrow HSCT
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Slease 1988 (Continued)
Outcomes survival; adverse events
Notes individual data for each participant reported
Sung 2003
Methods Prospective phase I study in a single centre in Korea from 1998 to 2001
Participants 26 participants with high-risk malignant solid tumors, of whom 2 children (1 male aged 20 months and 1 female
aged 47 months) with NRSTS (malignant fibrous histiocytoma; rhabdoid sarcoma)
Interventions successive double HDCT followed by autologous peripheral HSCT
Outcomes overall survival; adverse events
Notes individual data
Watanabe 2006
Methods Retrospective report of a case without control in a single-centre study, observed in Japan; information on observation
period not available
Participants 1 child (male) 1 year of age with rhabdoid sarcoma
Interventions HDCT followed by autologous peripheral HSCT
Outcomes survival; adverse events
Notes
Yamamura 2003
Methods Retrospective report of a single case in a single centre, observed in Japan in 1996
Participants 1 adult (male) 33 years of age with malignant fibrous histiocytoma
Interventions HDCT followed by autologous peripheral HSCT
Outcomes overall survival; adverse events
Notes reports on the development of chronic myelocytic leukemia following chemotherapy
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Yonemoto 1999
Methods Retrospective report of cases without control in a single-centre study, observed in Japan from 1995
Participants 3 young adults (3 male; 0 female) from 17 to 40 years of age with synovial sarcoma, of a total of 10 participants with
sarcomas
Interventions HDCT followed by autologous HSCT
Outcomes adverse events
Notes individual data
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Abdel-Dayem 1999 not intervention of interest
Abidi 2007 not diagnosis of interest
ABMTR 1986 not study design of interest (review)
ABMTR 1989 not diagnosis of interest
Abrahamsen 2000 data of interest not described separately
Admiraal 2007 not diagnosis of interest (rhabdomyosarcoma)
Aleinikova 2002 not diagnosis of interest (rhabdomyosarcoma)
Alpers 1982 not intervention of interest
Anderson 2005 not study design of interest
Antman 1987 not study design of interest (review)
Antman 1990 not intervention of interest
Antman 2001 not study design of interest (review)
Ashihara 2002 not diagnosis of interest (rhabdomyosarcoma)
Atra 1996 not study design of interest (review)
Atra 2002 not study design of interest (review)
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Avramova 2006 follow-up of study Michalov 2001
Bader 1989 not diagnosis of interest (rhabdomyosarcoma)
Bagnulo 1985 not diagnosis of interest (rhabdomyosarcoma)
Bambakidis 2002 not diagnosis of interest
Banna 2007 not study design of interest (review)
Barfield 2008 not study design of interest (review)
BCBS MAP 1999 not diagnosis of interest
Beaujean 1989 not diagnosis of interest (rhabdomyosarcoma)
Bellmunt 1997 data of interest not described separately
Bertuzzi 2002 data of interest not described separately
Beschorner 2006 not diagnosis of interest
Bezwoda 1994 not diagnosis of interest
Bickert 2002 not study design of interest (review)
Bien 2007 not diagnosis of interest (rhabdomyosarcoma)
Bini-Antunes 2006 not diagnosis of interest
Bisogno 2009 not disease of interest (rhabdomyosarcoma)
Blay 1994 not study design of interest (abstract)
Blay 2000 not disease of interest for 11 of 30 (36%) patients: 5 patients with rhabdomyosarcoma, 3 patients with
unclassified sarcoma, 1 paraganglioma, 1 Schwannosarcoma, and 1 peripheral neuroectodarmal tumorwere
included in a total of 30 analyzed patients
Bode-Lesniewska 2005 not intervention of interest
Bodey 1981 not diagnosis of interest
Bojko 2002 not diagnosis of interest
Bokemeyer 1997 not diagnosis of interest
Borden 1987 not intervention of interest
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Boulad 1998 data of interest not described separately
Bramwell 1986 not intervention of interest
Bramwell 1987 not intervention of interest
Bramwell 2001 not intervention of interest
Breitfeld 2001 not intervention of interest
Brugger 1995 not outcome of interest; paper retracted
Brugieres 1988 not diagnosis of interest (rhabdomyosarcoma)
Brun 1984 not intervention of interest
Bylund 2008 not intervention of interest
Cacchione 2008 data of interest not described separately
Caglar 2002 not diagnosis of interest
Carli 1988 not intervention of interest
Carli 1999 not diagnosis of interest (rhabdomyosarcoma)
Casado 2004 not study design of interest (review)
Casanova 2009 not disease of interest
Casper 1991 not intervention of interest
Ceschel 2006 data of interest not described separately
Chan 1991 not diagnosis of interest (rhabdomyosarcoma)
Chan 1999 not intervention of interest
Chang 1979 not intervention of interest
Chang 1979a not intervention of interest
Chang 1981 not intervention of interest
Chang 1988 not intervention of interest
Chauvin 1991 not study design of interest (abstract)
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Chen 1999 not study design of interest (review)
Chen 2008 not intervention of interest
Childs 2004 not study design of interest (review)
Cho 2005 data of interest not described separately
Chuman 2000 not study design of interest (review)
Clausen 1993 data of interest not described separately
Corbett 2009 not study design of interest (review)
Coulibalya 2008 not intervention of interest
Couzin 2007 not study design of interest (review)
Czyzewski 1999 data of interest not described separately
Dagher 1997 not intervention of interest
Dallorso 1996 not diagnosis of interest (rhabdomyosarcoma)
Dallorso 2000 not study design of interest (review)
Dantonello 2008 not intervention of interest
De Kraker 1984 not diagnosis of interest
De Pasquale 2003 not outcome of interest
De Sio 2006 not diagnosis of interest (rhabdomyosarcoma)
De Terlizzi 1988 not study design of interest (review)
De Vries 1995 not diagnosis of interest
Demirci 2003 not diagnosis of interest
Demirer 2008 not intervention of interest
Devalck 1992 not study design of interest (review)
Diaz 1999 not diagnosis of interest (rhabdomyosarcoma)
Dicke 1984 not study design of interest (review)
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Dicke 1986 not study design of interest (review)
Dileo 2005 not study design of interest (review)
Dillman 1995 data of interest not described separately
Dincol 2000 not intervention of interest
Donaldson 2001 not intervention of interest
Donker 2009 not intervention of interest (allogeneic)
Drabko 2006 not diagnosis of interest (rhabdomyosarcoma)
Dumontet 1992 not diagnosis of interest (rhabdomyosarcoma)
Ederhy 2007 not diagnosis of interest
Eggermont 1997 not intervention of interest
Ek 2006 not study design of interest (review)
Ekert 1982 duplicate publication of study Ekert 1984
Ekert 1984 not diagnosis of interest (rhabdomyosarcoma)
Elias 1998 not study design of interest (review)
Emminger 1991 not diagnosis of interest (rhabdomyosarcoma)
Endo 1995 not study design of interest (review)
Erkisi 1996 not intervention of interest
Espinosa 2001 not diagnosis of interest
Fazekas 2008 not diagnosis of interest
Fekrat 1993 not diagnosis of interest (rhabdomyosarcoma)
Ferrari 2005 not outcome of interest
Fetscher 1996 not study design of interest (abstract)
Figuerres 2000 data of interest not described separately
Fizazi 1994 not intervention of interest
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Flamant 1998 data of interest not described separately
Foncillas 2004 not diagnosis of interest (rhabdomyosarcoma)
Frustaci 2001 not intervention of interest
Fujita 2005 not diagnosis of interest
Gadner 2002 not study design of interest (review)
Garaventa 1986 not diagnosis of interest (rhabdomyosarcoma)
Garaventa 1987 not diagnosis of interest (rhabdomyosarcoma)
Gardner 2008 not diagnosis of interest
Gebhardt 1999 not intervention of interest
Geisler 2003 not diagnosis of interest
Geissler 1984 not intervention of interest
Gentet 1993 not study design of interest (review)
Ghalie 1994 not diagnosis of interest
Ghavamzadeh 2009 not diagnosis of interest (rhabdomyosarcoma)
Glenn 1985 not intervention of interest
Gonzalez 1989 not diagnosis of interest (rhabdomyosarcoma)
Gortzak 2001 not intervention of interest
Goto 2004 not study design of interest (review)
Graham 1992 not diagnosis of interest (rhabdomyosarcoma)
Graham-Pole 1995 not study design of interest (abstract)
Gratwohl 2002 not outcome of interest
Gratwohl 2004 not study design of interest (review)
Gratwohl 2004a not study design of interest (review)
Gratwohl 2004b not outcome of interest
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Gratwohl 2006 not outcome of interest
Gratwohl 2007 not study design of interest (review)
Gratwohl 2007a not study design of interest (review)
Grundy 2001 not diagnosis of interest (rhabdomyosarcoma)
Haas 1990 not diagnosis of interest
Hale 2005 not study design of interest (review)
Hara 1998 not diagnosis of interest (rhabdomyosarcoma)
Harmon 2001 not intervention of interest
Hartmann 1986 not diagnosis of interest (rhabdomyosarcoma)
Hartmann 1997 data of interest not described separately
Hartmann 2001 not diagnosis of interest
Hartmann 2005 not diagnosis of interest
He 1999 not intervention of interest
Hensel 2002 not diagnosis of interest
Herzog 2005 not study design of interest (review)
Hilden 1998 not diagnosis of interest
Hilden 2004 not diagnosis of interest
Hiraiwa 1983 not diagnosis of interest
Hoekstra 1994 not study design of interest (review)
Holtta 2005 not diagnosis of interest (rhabdomyosarcoma)
Holtta 2005a not diagnosis of interest (rhabdomyosarcoma)
Horn 2002 data of interest not described separately
Horowitz 1993 not diagnosis of interest (rhabdomyosarcoma)
Hosoi 2007 not diagnosis of interest (rhabdomyosarcoma)
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Hotte 2004 data of interest not described separately
Hoy 2007 not diagnosis of interest
Huang 2006 not diagnosis of interest (rhabdomyosarcoma)
Huttmann 2005 not diagnosis of interest
Höffken 1997 not study design of interest (review)
Iankelevich 2000 not outcome of interest
ICR 1994 not diagnosis of interest (rhabdomyosarcoma)
Imbach 1979 not diagnosis of interest
Irle 1989 not study design of interest (review)
Issels 1995 not study design of interest (review)
Issels 2002 not intervention of interest
Issels 2004 not study design of interest (review)
Jamil 2004 data of interest not described separately
Jelic 1994 not intervention of interest
Jelic 1997 not intervention of interest
Kaatsch 2009 not test intervention of interest
Kabickova 2003 data of interest not described separately
Kadan-Lottick 2008 not outcome of interest
Kaizer 1979 not diagnosis of interest (rhabdomyosarcoma)
Kaizer 1980 duplicate paper of Kaizer 1979
Kaizer 1984 not study design of interest (review)
Kalwak 2002 not diagnosis of interest (rhabdomyosarcoma)
Kanabar 1995 not diagnosis of interest (rhabdomyosarcoma)
Kasper 2004 data included in follow-up paper Kasper 2008
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Kasper 2005 not study design of interest (review)
Kasper 2006 data included in follow-up paper Kasper 2008
Katzenstein 2003 not study design of interest
Kavan 1997 not study design of interest (review)
Kavan 1997a not diagnosis of interest (rhabdomyosarcoma)
Kinsella 1988 not diagnosis of interest (rhabdomyosarcoma)
Kinsella 1988a data of interest not described separately
Klaritsch 2006 not diagnosis of interest
Kletzel 1997 not study design of interest (review)
Kletzel 1998 not diagnosis of interest (rhabdomyosarcoma)
Kletzel 2005 not study design of interest (review)
Klingebiel 1989 not study design of interest (review)
Klingebiel 1994 not study design of interest (review)
Klingebiel 2008 not diagnosis of interest (rhabdomyosarcoma)
Kook 1998 not diagnosis of interest
Korfel 2001 not diagnosis of interest (rhabdomyosarcoma)
Koscielniak 1992 data of interest not described separately
Koscielniak 1997 not diagnosis of interest (rhabdomyosarcoma)
Koscielniak 1999 not study design of interest (review)
Koscielniak 2001 not study design of interest (review)
Koscielniak 2002 not study design of interest (review)
Koscielniak 2005 not study design of interest (review)
Kuroiwa 2009 not diagnosis of interest (rhabdomyosarcoma)
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Kushner 2000 not study design of interest (review)
Kwan 1996 not diagnosis of interest (rhabdomyosarcoma)
Kwon 2010 not disease of interest (rhabdomyosarcoma, neuroblastoma)
Ladenstein 1993 not study design of interest (review)
Ladenstein 1997 not study design of interest (review)
Lal 2005 data of interest not described separately
Lang 2006 not diagnosis of interest (rhabdomyosarcoma)
Lange 2004 not intervention of interest (allogeneic HSCT)
Larsen 2000 not diagnosis of interest (rhabdomyosarcoma)
Le Cesne 2000 not intervention of interest
Le Corroller 1997 data of interest not described separately
Lehrnbecher 2006 not diagnosis of interest
Lessnick 2009 not study design of interest (review)
Liseth 2004 data of interest not described separately
Locatelli 2008 not intervention of interest (allogeneic HSCT)
Lorenz 1999 not study design of interest (review)
Lorigan 2007 not intervention of interest
Lucidarme 1998 not diagnosis of interest (rhabdomyosarcoma)
Mace 2003 not intervention of interest
Machado 2007 not diagnosis of interest
Mack 1995 not study design of interest (review)
Mackall 2001 not study design of interest (review)
Madero 1995 not diagnosis of interest (rhabdomyosarcoma)
Maeda 2008 not study design of interest (review)
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Mankin 2004 not intervention of interest
Marina 1997 not study design of interest (review)
Matsubara 2003 not diagnosis of interest (rhabdomyosarcoma)
Matsuyama 2000 not study design of interest (review)
Matthews 2007 not diagnosis of interest
Medioni 2003 not intervention of interest
Mesia 1995 not diagnosis of interest (rhabdomyosarcoma)
Meyers 2004 not study design of interest (review)
Michailov 2001 not diagnosis of interest (rhabdomyosarcoma)
Michon 1999 not study design of interest (review)
Mikhailova 1998 not outcome of interest
Miliauskas 1993 not intervention of interest
Mimeault 2008 not study design of interest (review)
Minard-Colin 2004 not intervention of interest
Mingo 2005 not intervention of interest
Miyagi 2003 not diagnosis of interest (rhabdomyosarcoma)
Moore 2009 not diagnosis of interest (rhabdomyosarcoma)
Morikawa 2005 not intervention of interest
Munoz 1983 not diagnosis of interest (rhabdomyosarcoma)
Müller 2002 not intervention of interest
Nachbaur 1994 not diagnosis of interest
Nag 1995 not diagnosis of interest (rhabdomyosarcoma)
Nath 2005 not diagnosis of interest (rhabdomyosarcoma)
Nenadov 1995 not diagnosis of interest (rhabdomyosarcoma)
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(Continued)
Nieboer 2005 not study design of interest (review)
Nieto 1999 not study design of interest (review)
Nieto 2004 not study design of interest (review)
Nieto 2007 data of interest not described separately
Nivison-Smith 2005 not outcome of interest
Nivison-Smith 2007 not outcome of interest
Nobile 1984 not intervention of interest
Notteghem 2003 not diagnosis of interest (rhabdomyosarcoma)
Oeffinger 2008 not study design of interest (review)
Ohira 1983 not diagnosis of interest (rhabdomyosarcoma)
Ohira 1990 not diagnosis of interest (rhabdomyosarcoma)
Ohta 2001 not diagnosis of interest (rhabdomyosarcoma)
Oppenheim 2002 not diagnosis of interest
Ortega 1991 not diagnosis of interest (rhabdomyosarcoma)
Osugi 2000 not diagnosis of interest (rhabdomyosarcoma)
Oue 2003 not diagnosis of interest (rhabdomyosarcoma)
Ozkaynak 1990 not intervention of interest
Ozkaynak 1998 not diagnosis of interest (rhabdomyosarcoma)
Ozkaynak 2008 data of interest not described separately
Pasetto 2003 not study design of interest (review)
Patel 1992 not study design of interest (review)
Patel 1994 not study design of interest (review)
Patzer 1999 not diagnosis of interest (rhabdomyosarcoma)
Paulides 2006 not intervention of interest
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(Continued)
Pedrazzoli 2006 not study design of interest (review)
Perentesis 1999 not diagnosis of interest (rhabdomyosarcoma)
Pession 1999 not diagnosis of interest (rhabdomyosarcoma)
Philip 1984 not study design of interest (review)
Pick 1988 not study design of interest (review)
Pico 1993 not diagnosis of interest (rhabdomyosarcoma)
Pinedo 1987 not intervention of interest
Pinkerton 1986 not study design of interest (review)
Pinkerton 1987 not study design of interest (review)
Pinkerton 1991 data of interest not described separately
Pinkerton 1991a not diagnosis of interest (rhabdomyosarcoma)
Pinkerton 1995 not study design of interest (review)
Pohar-Marinsek 2001 not diagnosis of interest (rhabdomyosarcoma)
Pohar-Marinsek 2003 not diagnosis of interest (rhabdomyosarcoma)
Raben 1994 not intervention of interest
Radeva 2005 not study design of interest
Raja 2003 not intervention of interest
Raney 1997 not diagnosis of interest (rhabdomyosarcoma)
Raney 2001 not study design of interest (review)
Rapidis 2008 not diagnosis of interest
Ray-Coquard 2001 not study design of interest (review)
Recchia 1996 not diagnosis of interest
Recchia 2003 not diagnosis of interest
Reich 2001 data of interest not described separately
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(Continued)
Reichardt 1997 not study design of interest (review)
Reichardt 2002 not study design of interest (review)
Rill 1994 not diagnosis of interest
Ritchie 2004 not diagnosis of interest (rhabdomyosarcoma)
Rivera-Luna 2001 not diagnosis of interest
Rodenhuis 1999 not study design of interest (review)
Roh 2001 not diagnosis of interest
Roman-Unfer 1996 not study design of interest (review)
Rosenberg 1981 not intervention of interest
Rosenberg 1982 not intervention of interest
Rosenberg 1983 not intervention of interest
Rosman 2008 data of interest not described separately
Rossbach 1999 not diagnosis of interest (rhabdomyosarcoma)
Rosti 2002 not study design of interest (review)
Rousselet 1994 not diagnosis of interest
Rubie 2003 not diagnosis of interest
Rzepecki 2006 not study design of interest (review)
Rzepecki 2006a not study design of interest (review)
Saikawa 2006 not diagnosis of interest (rhabdomyosarcoma)
Sajedi 2002 not intervention of interest (allogeneic HSCT)
Sakayama 2008 not diagnosis of interest (rhabdomyosarcoma)
Salutari 1998 not diagnosis of interest (rhabdomyosarcoma)
Sanchez 1986 not study design of interest (review)
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(Continued)
Sanchez-Garcia 2007 not diagnosis of interest
Santana 1992 not diagnosis of interest (rhabdomyosarcoma)
Sanz 1997 not diagnosis of interest (rhabdomyosarcoma)
Sato 1998 not diagnosis of interest (rhabdomyosarcoma)
Sauer 1998 not study design of interest (review)
Sauer 1998a not study design of interest (review)
Savasan 2005 not study design of interest (review)
Savolainen 2005 not diagnosis of interest (rhabdomyosarcoma)
Sawyer 1999 not study design of interest (review)
Schimmer 2002 data of interest not described separately
Schlemmer 2006 not disease of interest for 22 of 55 (40%) patients: 3 patients with rhabdomyosarcoma, 3 patients with
peripheral neuroectodarmal tumor, and 16 patients with not identified tumors were included in a total of
55 analyzed patients
Schmidt 1994 not intervention of interest (allogeneic HSCT)
Schulz 1991 data of interest not described separately
Schuster 2008 data of interest not described separately
Schwella 1998 data of interest not described separately
Secondino 2007 not intervention of interest (allogeneic HSCT)
Seeger 1991 not study design of interest (review)
Segura 2001 not diagnosis of interest (rhabdomyosarcoma)
Seregard 2002 not diagnosis of interest (rhabdomyosarcoma)
Seynaeve 1999 not study design of interest
Shea 1995 not diagnosis of interest
Shen 1993 duplicate paper of Shen 1994
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(Continued)
Shen 1994 not intervention of interest (allogeneic HSCT)
Shimizu 2008 not diagnosis of interest (rhabdomyosarcoma)
Shinkoda 2009 not diagnosis of interest (rhabdomyosarcoma)
Simon 2007 data of interest not described separately
Skinner 1974 not intervention of interest
Sola 1999 not diagnosis of interest
Somlo 1995 not intervention of interest
Spitzer 1980 not diagnosis of interest
Spitzer 1984 not diagnosis of interest
Spitzer 1994 not study design of interest (review)
Spitzer 1995 not diagnosis of interest
Spruce 1983 not study design of interest (review)
Stea 1987 not diagnosis of interest (rhabdomyosarcoma)
Steinbrenner 2005 data of interest not described separately
Stöhr 2006 not intervention of interest
Suita 2005 not diagnosis of interest (rhabdomyosarcoma)
Sussman 2008 not study design of interest (review)
Takata 1997 not intervention of interest
Takaue 2002 not diagnosis of interest (rhabdomyosarcoma)
Takenaka 2007 not intervention of interest
Tang 2009 not disease of interest (rhabdomyosarcoma)
Thomson 1999 not diagnosis of interest (rhabdomyosarcoma)
Toma 1992 not intervention of interest
Trigg 2002 not study design of interest (review)
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(Continued)
Unal 2006 data of interest not described separately
Urban 1997 not outcome of interest
Urbano-Ispizua 2002 not outcome of interest
Vadhan 1996 not study design of interest (abstract)
Vadhan-Raj not intervention of interest
Valkova 2003 not intervention of interest
Valteau-Couanet 2007 not study design of interest (review)
Valteau-Couanet 2007a not diagnosis of interest
Van Dalen 2009 not intervention of interest
Van den Berg 2006 not study design of interest (review)
Van den Berg 2007 not study design of interest (review)
Van den Berg 2008 not intervention of interest
Van Glabbeke 1993 not intervention of interest
Varterasian 1997 not intervention of interest
Vassal 2005 not study design of interest (review)
Vaughan 2001 not study design of interest (review)
Verma 2002 not study design of interest (review)
Verma 2008 not study design of interest (review)
Verma 2008a not study design of interest (review)
Wachowiak 2008 not outcome of interest
Walterhouse 1999 not diagnosis of interest (rhabdomyosarcoma)
Wasserman 1997 not diagnosis of interest
Watanabe 2006a not study design of interest
Weaver 1997 data of interest not described separately
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(Continued)
Weh 1995 not study design of interest (review)
Weh 1996 not intervention of interest
Weigel 2001 not study design of interest (review)
Werchniak 2005 not diagnosis of interest
Wexler 1996 not intervention of interest
Willenbacher 1998 data of interest not described separately
Williams 2004 not diagnosis of interest (rhabdomyosarcoma)
Womer 1996 not study design of interest (review)
Womer 2000 not study design of interest (review)
Woods 1999 not study design of interest (review)
Worden 2005 not intervention of interest
Yamada 2007 not diagnosis of interest (rhabdomyosarcoma)
Yaniv 1990 not study design of interest (review)
Yaniv 2000 not study design of interest (review)
Yaqoob 2006 not study design of interest (review)
Yin 2009 not intervention of interest
Young 1989 data of interest not described separately
Zoubek 1994 not intervention of interest
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D A T A A N D A N A L Y S E S
This review has no analyses.
A D D I T I O N A L T A B L E S
Table 1. Frequency of subtypes of included NRSTS in patients of young versus advanced age
Young age (< 20 years) Advanced (≥ 20 years)
Subtype % Subtype %
Synovial sarcoma 7.7 Leiomyosarcoma 13.7
Malignant fibrous histiocytoma 4.9 Malignant fibrous histiocytoma 10.1
Fibrosarcoma 4.5 Liposarcoma 8.0
Liposarcoma 2.8 Hemangiosarcoma 2.5
Epitheloid sarcoma 2.0 Spindle cell sarcoma 2.3
*according to Spunt 2006
Table 2. Included non-rhabdomyosarcoma soft tissue sarcomas (NRSTS)
Diagnosis(*)
Alveolar soft part sarcoma
Anaplastic soft tissue sarcoma
Angiosarcoma
1. Angiosarcoma of soft tissue
2. Hemangiosarcoma
3. Hemangiopericytoma
4. Lymphangiosarcoma
Clear cell myomelanocytic tumor
Clear cell sarcoma of soft tissue
Desmoplastic small round cell tumor
Epithelioid sarcoma
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Table 2. Included non-rhabdomyosarcoma soft tissue sarcomas (NRSTS) (Continued)
Fibrosarcoma
1. Adult fibrosarcoma
2. Myxofibrosarcoma
3. Low grade fibromyxoid sarcoma; hyalinizing spindle cell tumor
4. Sclerosing epithelioid fibrosarcoma
Fibromyxoid sarcoma
Epithelioid hemangioendothelioma
Intimal sarcoma
Leiomyosarcoma
1. Leiomyosarcoma (excluding skin)
Liposarcoma
1. Dedifferentiated liposarcoma
2. Myxoid liposarcoma
3. Round cell liposarcoma
4. Pleomorphic liposarcoma
5. Mixed-type liposarcoma
6. Liposarcoma, not otherwise specified
Mesenchymal sarcoma
Malignant glomus tumor
Malignant fibrous histiocytoma
1. Pleomorphic malignant fibrous histiocytoma; undifferentiated pleomorphic sarcoma
2. Giant cell malignant fibrous histiocytoma; undifferentiated pleomorphic sarcoma with giant cells
3. Inflammatory malignant fibrous histiocytoma; undifferentiated pleomorphic sarcoma with prominent inflammation
4. Undifferentiated pleomorphic sarcoma
5. Spindle cell sarcoma
Malignant haemangiopericytoma
Malignant mesenchymoma
Neoplasms with perivascular epithelioid cell differentiation (PEComa)
Rhabdoid sarcoma
1. Extra-renal rhabdoid tumor
Synovial sarcoma
Unclassified sarcoma
Undifferentiated sarcoma
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* category of malignant tumors according to theWorld Health Organization Classification of Tumours: Pathology and Genetics of Tumours
of Soft Tissue and Bone (Fletcher 2002)
Table 3. Excluded tumor types
Diagnosis Reason for exclusion(*)
Atypical teratoid/rhabdoid tumors WHO classification of tumors of the central nervous system
Chondrosarcoma
1. Mesenchymal chondrosarcoma
2. Extraskeletal myxoid chondrosarcoma (’chordoid type’)
Extraskeletal types are difficult to separate
Dermatofibrosarcoma protuberance WHO classification of tumors of the skin
Endometrial stroma sarcoma WHO classification of tumors: pathology and genetics of tumors
of the breast and female genital organs
Ewing family of tumors
1. Ewing sarcoma
2. Skeletal Ewing’s sarcoma
3. Extraskeletal Ewingsarcoma
4. Peripheral primitive neuroectodermal tumour (pPNET)
5. Extraskeletal peripheral primitive neuroectodermal tumor
(pPNET)
6. Askin tumor
Extraskeletal types are difficult to separate; the Ewing family of
tumors is one entity
Extragonadal germ cell sarcoma WHO classification of tumors: pathology and genetics of tumors
of the urinary system and male genital organs
WHO classification of tumors: pathology and genetics of tumors
of the breast and female genital organs
Follicular dendritic cell sarcoma WHO classification of tumors of hematopoietic and lymphoid
tissues
Ganglioneuroblastoma WHO classification of nervous system tumors
Gastrointestinal stromal tumor WHO classification of tumors: pathology and genetics of tumors
of the digestive system
Giant cell fibroblastoma WHO classification of tumors of the skin
Giant cell tumour of bone WHO classification for tumors of bone tissue
Histiocytic sarcoma WHO classification of tumors of hematopoietic and lymphoid
tissues
Interdigitating dendritic cell sarcoma WHO classification of tumors of hematopoietic and lymphoid
tissues
78Autologous hematopoietic stem cell transplantation following high-dose chemotherapy for non-rhabdomyosarcoma soft tissue sarcomas
(Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Table 3. Excluded tumor types (Continued)
Interdigitating reticulum cell sarcoma WHO classification of tumors of hematopoietic and lymphoid
tissues
Kaposi sarcoma Intermediate malignancy (rarely metastasizing)
Lymphoblastic lymphosarcoma WHO classification of tumors of hematopoietic and lymphoid
tissues
Medulloblastoma WHO classification of tumors of the central nervous system
Myeloid sarcoma WHO classification of tumors of hematopoietic and lymphoid
tissues
Myxosarcoma (cardiac tumor) WHO classification of tumors: pathology and genetics of tumors
of the lung, pleura, thymus and heart
Nephroblastoma WHO classification of tumors: pathology and genetics of tumors
of the urinary system and male genital organs
Neuroblastoma (Wilms tumor) WHO classification of tumors: pathology and genetics of tumors
of the urinary system and male genital organs
Osteosarcoma
1. Extraskeletal osteosarcoma
Extraskeletal types are difficult to separate
Peripheral nerve sheath tumor, malignant (neurofibrosarcoma) WHO classification of nervous system tumors
Rhabdoid tumour, renal WHO classification of tumors: pathology and genetics of tumors
of the urinary system and male genital organs
Rhabdoid tumour, cerebral WHO classification of tumors of the central nervous system
Rhabdomyosarcoma
1. Embryonal rhabdomyosarcoma (including spindle cell,
botryoid, anaplastic)
2. Alveolar rhabdomyosarcoma (including solid, anaplastic)
3. Pleomorphic rhabdomyosarcoma
4. Undifferentiated rhabdomyosarcoma
A soft tissue sarcoma that is excluded to separate rhabdomyosar-
comas from non-rhabdomyosarcoma soft tissue sarcomas
Schwannoma, malignant WHO classification of nervous system tumors
Uterine endometrial stromal sarcoma WHO classification of tumors: pathology and genetics of tumors
of the breast and female genital organs
* WHO: World Health Organization
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Table 4. Literature sources and search steps
Category Sources
Step 1
Bibliographic databases 1. MEDLINE via Ovid; via PubMed, includes Clinical Queries
2. EMBASE via Ovid
3. The Cochrane Library via Wiley InterScience
i) Cochrane central register of controlled trials
ii) Cochrane database of systematic reviews (CDSR; Cochrane reviews)
iii) database of abstracts of reviews of effects (DARE; other reviews)
iv) health technology assessment database (HTA; technology assessments)
v) National Health Services economic evaluation database (NHSEED; economic evaluations)
Step 2
Online trial registers 1. ClinicalTrials.gov (ClinicalTrials.gov 2010)
2. International Standard Randomised Controlled Trial Number (ISRCTN 2010) Register
3. National Institute for Health Research UK Clinical Research Network’s (NIHR UKCRN 2010)
Portfolio Database
4. National Cancer Institute Physician Data Query (NCI PDQ 2010) Clinical Trials
5. European Group for Blood and Marrow Transplantation Solid Tumor Working Party (EBMT
STWP 2010)
6. World Health Organization International Clinical Trials Registry Platform (ICTRP 2010)
Step 3
Reviews systematic reviews (rhabdomyosarcoma included): Admiraal 2007 (Cochrane Protocol); Verma 2008;
Weigel 2001
narrative reviews (rhabdomyosarcoma included): 95 articles from 1983 to 2008
Step 4
Congress proceedings Blood (American Society of Hematology Annual Meeting Abstracts) 2004 to 2007
Step 5
Institutions(*) 1. Scientific Institute San Raffaele, Milan, Italy
2. Istituto Nazionale dei Tumori, Milan, Italy
3. Deutsche Gesellschaft für Hämatologie und Onkologie (DGHO), Berlin, Germany
4. St. Jude Children’s Research Hospital, Memphis, Tennessee, USA
5. Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany
6. National CancerCenter Hospital, Tokyo, Japan
7. Memorial Sloan-Kettering Cancer Center, New York City, New York, USA
8. European Group for Blood and Marrow Transplantation (EBMT), Leipzig, Germany
9. Ospedale Niguarda Ca’Granda, Milano, Italy
10. Universitätsklinikum Charite, Berlin, Germany
11. Medizinische Universitätsklinik, Ulm, Germany
12. Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
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Table 4. Literature sources and search steps (Continued)
13. Italian sarcoma Group (ISG), Bologna, Italy
Step 6
Authors(*) Blay 2000; Ivanova 2007; Kasper 2007; Kasper 2009; Schlemmer 2006; Simon 2007; Suita 2005
* direct enquiries by e-mail and post
Table 5. Assessment of risks of bias
Type of comparative study Randomized controlled intervention
trial
Non-randomized comparative interven-
tion studies
• non-randomized controlled clinical
intervention trial
• prospective cohort study
• retrospective cohort study
• case-control study
Assignment of patients to treatment groups Was the allocation sequence adequately
generated?
• yes
◦ e.g. participants assigned to
treatments on basis of a computer-
generated random sequence or a table of
random numbers
• unclear
◦ e.g. not reported, information
not available
An answer no would mark a non-random-
ized study and, therefore, this option is not
provided
Were relevant details of criteria for assign-
ment of patients to treatment groups pro-
vided?
• yes
◦ e.g. participants assigned
alternating to treatments on basis of date
of birth, clinic id-number or surname, at
the discretion of the responsible physician,
or no attempt to randomise participants
• no
• unclear
Concurrent control not applicable Were data of the control group collected
during the same time period as data of the
test group?
• yes
• no
◦ historical control data collected
earlier than for the test group
• unclear
Concealment of allocation Was allocation adequately concealed?
• yes
◦ e.g. where the allocation
sequence could not be foretold
• no
◦ e.g. allocation sequence could
be foretold by patients, investigators or
not applicable
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Table 5. Assessment of risks of bias (Continued)
treatment providers
• unclear
◦ e.g. not reported
Comparable baseline characteristics Were the two treatment groups comparable? Were the groups balanced in respect to
confounders? Were there no differences of baseline characteristics between the two treat-
ment groups or were differences controlled for, in particular with reference to prognostic
factors, such as, age, gender, histological diagnosis, year of transplantation?
• yes
◦ groups were comparable or differences between groups were considered (e.g.
adjusted for), or factors were matched and groups were balanced in respect to
confounders
• no
◦ if the two groups differed and differences were not controlled for
• unclear
Loss to follow-up Was loss to follow-up less than 20% and were the reasons for loss to follow-up similar
in both arms?
• yes
• no
• unclear
Selective outcome reporting Are reports of the study free of suggestion of selective outcome reporting?
• yes
• no
◦ e.g if protocol reports all outcomes specified in the protocol
• unclear
Other causes for high risk of bias Was the study apparently free of other problems that could put it at a high risk of bias?
• yes
• no
• unclear
Table 6. Overall survival (OS) and progression-free survival (PFS)
Study Follow up started at OS PFS
2 years 2 years
Controlled trials (HSCT after HDCT versus standard-dose chemotherapy)
Ivanova 2007 unclear 62.3% vs. 23.2%∗ -
No control group (only patients with HSCT after HDCT)
Bertuzzi 2003 “therapy” 20%† 0%†
Pooled meta-analysis of individual data (only patients with HSCT after HDCT)
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Table 6. Overall survival (OS) and progression-free survival (PFS) (Continued)
54 patients (29 studies) HSCT 49% (95% CI: 34% to 64%) -
∗ “statistically significant”, no detailed description of statistical method
† reading from Kaplan-Meier curve
Table 7. Treatment-related mortality (TRM) in transplanted patients
Study TRM, n Cause of death
No control group, individual data (only patients with HSCT)
Doros 2008 1 not specified
Engelhardt 2007 3 (1) sepsis; (2) sepsis; (3) pulmonary metastases, pneumonia, respiratory failure
Kasper 2007 1 cardiac arrest of unknown origin
Navid 2006 1 hepatic and renal failure
Saab 2007 2 (1) acute myocardial infarction; (2) veno-occlusive disease
Shaw 1996 1 veno-occlusive disease and necrotising interstitial pneumonitis
Slease 1988 2 (1) progressive encephalopathy; (2) sepsis
Table 8. Secondary neoplasia in transplanted patients
Study Secondary neoplasia, n Diagnosis
No control group, individual data (only patients with HSCT)
Yamamura 2003 1 chronic myelogenous leukemia
Table 9. Toxicity, National Cancer Institute (NCI) common terminology criteria for adverse events (CTCAE) grade 3-4, in
transplanted patients
Study Hematological toxicity
(Number of affected / total patients)
Non-hematological toxicity
(Number of affected / total patients)
Leukopenia Neutrope-
nia
Throm-
bopenia
Nausea Kidney Liver Nervous
system
Heart
No control group, individual data (only patients with HSCT)
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Table 9. Toxicity, National Cancer Institute (NCI) common terminology criteria for adverse events (CTCAE) grade 3-4, in
transplanted patients (Continued)
Kasper 2007 14 / 14 14 / 14 14 / 14 - - - - -
Kozuka
2002
- 1 / 1 1 / 1 1 / 1 - - - -
Kushner
2001
- - - - - - 1 / 1 -
Patel 2004 - - - - 1 / 1 1 / 1 - -
Yonemoto
1999
- - - - - 1 / 4 - -
A P P E N D I C E S
Appendix 1. MEDLINE/Ovid search strategy
1. exp SARCOMA/
2. (sarcom$ or sarkom$).mp.
3. exp LIPOSARCOMA/
4. liposar#om$.mp.
5. exp FIBROSARCOMA/
6. fibrosar#om$.mp.
7. exp HISTIOCYTOMA, MALIGNANT FIBROUS/
8. malign$ fibrous histio#ytom$.mp.
9. exp LEIOMYOSARCOMA/
10. leiomyosar#om$.mp.
11. malign$ glom$ tumo$.mp.
12. exp RHABDOMYOSARCOMA/
13. rhabdomyosar#om$.mp.
14. exp HEMANGIOENDOTHELIOMA/
15. (hemangioendotheliom$ or haemangioendotheliom$).mp.
16. exp HEMANGIOSARCOMA/
17. (angiosar#om$ or hemangiosar#om$ or haemangiosar#om$).mp.
18. exp SARCOMA, SYNOVIAL/
19. synovia$ sar#om$.mp.
20. epithelioid sar#om$.mp.
21. exp SARCOMA, ALVEOLAR SOFT PART/
22. (alveolar soft part sar#om$ or alveolar soft tissue sar#om$).mp.
23. exp SARCOMA, CLEAR CELL/
24. clear cell sar#om$.mp.
25. exp SARCOMA, SMALL CELL/
26. (desmoplastic and small round cell tumo$ or small cell tumo$)).mp.
27. exp RHABDOID TUMOR/
28. ((extrarenal or extra-renal) and rhabdoid tumo$).mp.
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29. (malignan$ and mesenchymom$).mp.
30. clear cell myomelano#ytic tumo$.mp.
31. intima$ sar#om$.mp.
32. exp STEM CELL TRANSPLANTATION/
33. exp BONE MARROW TRANSPLANTATION/
34. exp TRANSPLANTATION, AUTOLOGOUS/
35. exp TRANSPLANTATION, HOMOLOGOUS/
36. exp TRANSPLANTATION, CONDITIONING/
37. (autolog$ hemato$ or autolog haemato$ or autolog$ stem cell or autolog$ bone marrow or autolog$ periph$ or autolog$
transplant$ or autolog$ graft$ or autotransplant$ or auto-transplant$ or autograft$ or auto-graft$).mp.
38. (homolog$ hemato$ or homolog$ haemato$ or homolog$ stem cell or homolog$ bone marrow or homolog$ cord or homolog$
umbilical or homolog$ peripheral or homolog$ transplant$ or homolog$ graft$ or homolog$ transplant$).mp.
39. (stem cell transplant$ or bone marrow transplant$ or periph$ blood stem cell or periph$ stem cell or cord blood transplant$).mp.
40. (reduced intens$ or myeloablat$ or nonmyeloablat$ or non-myeloablat$).mp.
41. high dose chemotherapy.mp.
42. or/1-31
43. or/32-41
44. and/42-43
45. (ANIMALS not (ANIMALS and HUMANS)).sh.
46. 44 not 45
Appendix 2. EMBASE/Ovid search strategy
1. exp SARCOMA/
2. (sarcom$ or sarkom$).mp.
3. exp LIPOSARCOMA/
4. liposar#om$.mp.
5. exp FIBROSARCOMA/
6. fibrosar#om$.mp.
7. exp MALIGNANT FIBROUS HISTIOCYTOMA/
8. malign$ fibrous histio#ytom$.mp.
9. exp LEIOMYOSARCOMA/
10. leiomyosar#om$.mp.
11. malign$ glom$ tumo$.mp.
12. exp RHABDOMYOSARCOMA/
13. rhabdomyosar#om$.mp.
14. exp HEMANGIOENDOTHELIOMA/
15. (hemangioendotheliom$ or haemangioendotheliom$).mp.
16. exp HEMANGIOENDOTHELIOSARCOMA/
17. (hemangioendotheliosar#om$ or haemangioendotheliosar#om$).mp.
18. exp ANGIOSARCOMA/
19. angiosar#om$.mp.
20. exp SYNOVIAL SARCOMA/
21. synovia$ sar#om$.mp.
22. exp EPITHELIOID SARCOMA/
23. (epithelioid$ sar#om$ or epitheloid$ sar#om$).mp.
24. exp ALVEOLAR SOFT PART SARCOMA/
25. (alveolar soft part sar#om$ or alveolar soft tissue sar#om$).mp.
26. exp CLEAR CELL SARCOMA/
27. clear cell sar#om$.mp.
28. exp DESMOPLASTIC SMALL ROUND CELL TUMOR/
29. exp SMALL CELL SARCOMA/
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30. (desmoplastic and (small round cell tumo$ or small cell tumo$)).mp.
31. ((extrarenal$ or extra-renal$) and rhabdoid$ tumo$).mp.
32. (malign$ and mesenchymom$).mp.
33. clear cell myomelano#yt$ tumo$.mp.
34. intima$ sar#om$.mp.
35. exp STEM CELL TRANSPLANTATION/
36. exp BONE MARROW TRANSPLANTATION/
37. exp NONMYELOABLATIVE STEM CELL TRANSPLANTATION/
38. exp NONMYELOBLATIVE CONDITIONING/
39. exp REDUCED INTENSITY CONDITIONING/
40. exp MYELOABLATIVE CONDITIONING/
41. (autolog$ hemato$ or autolog haemato$ or autolog$ stem cell or autolog$ bone marrow or autolog$ periph$ or autolog$
transplant$ or autolog$ graft$ autotransplant$ or auto-transplant$ or autograft$ or auto-graft$).mp.
42. (homolog$ hemato$ or homolog$ haemato$ or homolog$ stem cell or homolog$ bone marrow or homolog$ cord or homolog$
umbilical or homolog$ periph$ or homolog$ transplant$ or homolog$ graft$).mp.
43. (stem cell transplant$ or bone marrow transplant$ or periph$ blood stem cell or periph$ stem cell or cord blood transplant$).mp.
44. (reduced intens$ or myeloablat$ or nonmyeloablat$ or non-myeloablat$).mp.
45. high dose chemotherapy.mp.
46. or/1-34
47. or/35-45
48. and/46-47
49. (ANIMALS not (ANIMALS and HUMANS)).sh.
50. 48 not 49
Appendix 3. Cochrane/Wiley search strategy
1. exp SARCOMA/
2. (sarcom$ or sarkom$).mp.
3. exp LIPOSARCOMA/
4. liposar#om$.mp.
5. exp FIBROSARCOMA/
6. fibrosar#om$.mp.
7. exp HISTIOCYTOMA, MALIGNANT FIBROUS/
8. malign$ fibrous histio#ytom$.mp.
9. exp LEIOMYOSARCOMA/
10. leiomyosar#om$.mp.
11. malign$ glom$ tumo$.mp.
12. exp RHABDOMYOSARCOMA/
13. rhabdomyosar#om$.mp.
14. exp HEMANGIOENDOTHELIOMA/
15. (hemangioendotheliom$ or haemangioendotheliom$).mp.
16. exp HEMANGIOSARCOMA/
17. (angiosar#om$ or hemangiosar#om$ or haemangiosar#om$).mp.
18. exp SARCOMA, SYNOVIAL/
19. synovia$ sar#om$.mp.
20. (epithelioid sar#om$ or epitheloid sar#om$).mp.
21. exp SARCOMA, ALVEOLAR SOFT PART/
22. (alveolar soft part sar#om$ or alveolar soft tissue sar#om$).mp.
23. exp SARCOMA, CLEAR CELL/
24. clear cell sar#om$.mp.
25. exp SARCOMA, SMALL CELL/
26. (desmoplastic and (small round cell tumo$ or small cell tumo$)).mp.
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27. exp RHABDOID TUMOR/
28. ((extrarenal or extra-renal) and rhabdoid tumo$).mp.
29. (malignan$ and mesenchymom$).mp.
30. clear cell myomelano#ytic tumo$.mp.
31. intima$ sar#om$.mp.
32. exp STEM CELL TRANSPLANTATION/
33. exp BONE MARROW TRANSPLANTATION/
34. exp TRANSPLANTATION, AUTOLOGOUS/
35. exp TRANSPLANTATION, HOMOLOGOUS/
36. exp TRANSPLANTATION, CONDITIONING/
37. (autolog$ hemato$ or autolog haemato$ or autolog$ stem cell or autolog$ bone marrow or autolog$ periph$ or autolog$
transplant$ or autolog$ graft$ or autotransplant$ or auto-transplant$ or autograft$ or auto-graft$).mp.
38. (homolog$ hemato$ or homolog$ haemato$ or homolog$ stem cell or homolog$ bone marrow or homolog$ cord or homolog$
umbilical or homolog$ periph$ or homolog$ transplant$ or homolog$ graft$).mp.
39. (stem cell transplant$ or bone marrow transplant$ or periph$ blood stem cell or periph$ stem cell or cord blood transplant$).mp.
40. (reduced intens$ or myeloablat$ or nonmyeloablat$ or non-myeloablat$).mp.
41. high dose chemotherapy.mp.
42. or/1-31
43. or/32-41
44. and/42-43
45. (ANIMALS not (ANIMALS and HUMANS)).sh.
46. 44 not 45
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